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Prostate cancer is initially androgen-dependent (AD) and therefore androgen deprivation therapy 
(ADT) is generally used to treat advanced prostate cancer. However, the long-term treatment 
effects are insufficient and over time an androgen-independent (AI) tumor relapses, which is 
generally highly aggressive and metastatic. Treatment regimens in the AI stage are only palliative 
and median patient survival is less than a year. Therefore, new treatment concepts are urgently 
needed. The purpose of this thesis was to investigate molecular and cellular characteristics of 
advanced prostate cancer. The specific focus was on characteristics related to invasivity and 
metastatic ability in the AI stage. An experimental model system comprising of an AD and an AI 
prostate cancer cell line was used for in vitro studies in cell culture and in vivo studies in 
immunodeficient mice. In addition, samples from prostate cancer patients were included in the 
studies and evaluated by immunohistochemical analyses. Studies performed using the 
experimental model showed that transition into androgen-independency was associated with 
several prometastatic alterations, including increased migration and tumor cell invasivity into 
blood vessels. Further, the AI tumors displayed elevated levels of N-cadherin, matrix 
metalloproteinase 9 (MMP-9) and membrane type-1(MT1)-MMP and decreased expression of the 
tumor suppressor E-cadherin compared to the AD tumors. Further studies demonstrated that 
intraprostatic AI tumors were suppressed when grown in intact mice compared to castrated mice, 
probably by androgen-regulated factors secreted from the prostatic stromal cells. In addition, the 
proinvasive factor N-cadherin was increased by androgen deprivation in experimental AI tumors 
and in samples from human prostate cancer. Similarly, N-cadherin was increased in specimens 
from AI prostate tumors compared to early non-treated tumors and was associated with Gleason 
score and metastasis. Finally, the results show that the lymphangiogenic factor vascular 
endothelial growth factor C (VEGF-C) and its receptor VEGFR-3 were elevated in primary 
tumors from patients with regional lymph node metastases compared to patients without lymph 
node metastases. In summary, this thesis shows that androgen deprivation and the subsequent 
development of AI tumors are associated with several prometastatic alterations in the prostate 
cancer cells. The results also suggest that AI tumors do not thrive in the prostatic environment 
and supports previous observations of frequent progression of AI prostate cancer as metastases in 
patients. Moreover, the results indicate a possible role for VEGF-C and N-cadherin in promoting 
dissemination of tumor cells to distant sites. Thus, N-cadherin and VEGF-C might be potential 
therapeutic targets for future anti-metastatic treatment for advanced prostate cancer. 
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DLP   Dorsolateral prostate 
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PSA   Prostate specific antigen 
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RT-PCR   Reverse transcriptase polymerase chain reaction 
SCID   Severe combined immunodeficiency 
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VEGF-C   Vascular endothelial growth factor C 
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The normal prostate gland 
 
 
Anatomy and physiology 
The prostate gland is a small, rounded organ with a diameter of approximately 4 
cm. It is positioned immediately below the urinary bladder, where it encircles the 
proximal portion of the urethra. The prostate consists of glands, smooth muscles 
and connective tissue and is enclosed by a fibrous capsule-like structure. The 
glandular ducts open up into urethra. The human prostate can be divided into three 
distinct zones; the peripheral zone, the transitional zone and the central zone.1 The 
peripheral zone is the largest and the most common origin of prostate cancer.2 
Studies of prostate cancer are often performed in rodent models. In contrast to 
humans, the rodent prostate gland consists of lobes; the anterior lobe, the dorsal and 
lateral lobe (collectively referred to as the dorsolateral lobe) and the ventral lobe.3,4 
There is no clear analogy between the lobular structure of the rodent prostate and 
the zonal architecture of the human prostate. However, studies indicate that the 
dorsolateral lobe is most similar to the human peripheral zone.4 
 
The prostatic glands produce a weakly alkaline secretion that contributes to about 
30% of the semen. The secretion contains protein and ions and function as a 
liquefying agent that assists in sperm motility and its alkalinity protects the sperm 
in their passage through the acidic environment of the female vagina. The secretion 
is ejected into the urethra by peristaltic contractions of the muscular wall. The 
serine protease prostate specific antigen (PSA), also known as kallikrein III is 
perhaps one of the most well known secreted protein from the prostate.5 The 
prostate gland remains relatively small throughout childhood and begins to grow at 
puberty under the stimulus of testosterone. It reaches an almost stationary size by 
the age of about 20 years and remains mostly at this size up to the age of about 50 
years. At that time, the prostate may start growing again, which sometimes leads to 





The glandular ducts are lined by a prostatic epithelium where three distinct cell 
types can be distinguished; luminal cells, basal cells and neuroendocrine cells 




terminally differentiated and characterised by the expression of the androgen 
receptor (AR).6 They produce PSA and prostatic acid phosphatase (PAP) and they 
are dependent on androgens for survival.7 The basal cells are relatively 
undifferentiated and they express low levels of AR8 but are not dependent on 
androgens for survival.6,7 They lack secretory function and expression of PSA. 
Their function is not fully understood but it is believed that a subset of the basal 
cells function as stem cells in the prostate.9 It has been suggested that the androgen-
independent (AI) prostate stem cells give rise to a population of androgen 
responsive transit amplifying cells that in turn can amplify the number of luminal 
cells.9,10 The characteristics of the transit amplifying cells are proposed to be 
intermediate between basal cells and luminal cells. Finally, the third prostatic 
epithelial cell type is the neuroendocrine cell, which are terminally differentiated 
and androgen-insensitive cells dispersed throughout the basal cell layer. They 
contain serotonin and thyroid-stimulating hormone that support the growth of the 
luminal cells.11 The stroma is composed of smooth muscle cells, endothelial cells, 
nerves, fibroblasts, dendritic cells and infiltrating immune cells. The fibroblastic 
stromal cells express AR and are androgen responsive.12-14 They produce growth 
factors for the epithelial cells in an androgen-dependent (AD) manner15 and the 
crosstalk between the stroma and epithelium is an important regulator of prostate 






Figure 1: Schematic illustration of 
the different cell types within the 
epithelium of a human prostate 
gland; luminal cells, basal cells and 




Regulation of the prostate gland 
Development and growth of the prostate gland is highly dependent on androgens. 
The production of androgens is regulated from hypothalamus by secretion of 
gonadotropin-releasing hormone (GnRH), which acts on the pituitary gland. The 
pituitary responds with secretion of luteinizing hormone (LH), which thereafter 
induces the secretion of testosterone from the Leydig cells of the testis. In addition, 
the hypothalamus release corticotropin-releasing hormone (CRH) that induces the 
secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland. ACTH 
influences the adrenal glands to produce testosterone and other weak androgens, for 
example adrenostenediol. Of the circulating testosterone, 95% originates from the 




Figure 2: The production of testosterone is under the superior control of the hypothalamus and 
the pituitary gland. The hypothalamus secretes GnRH and CRH that influences the pituitary to 
produce LH and ACTH, respectively. LH influences the testis to produce testosterone and ACTH 
regulates the production of testosterone and other weak androgens from the adrenal glands. The 
majority of the testosterone originates from the testis. GnRH = gonadotropin-releasing hormone; 
CRH = corticotropin-releasing hormone; LH = luteinizing hormone; ACTH = adrenocorticotropic 
hormone. 
 
Circulating testosterone diffuses into the epithelial and stromal cells of the prostate 
where it is converted by the enzyme 5α-reductase into dihydrotestosterone (DHT). 
Both testosterone and DHT can bind the AR, but DHT has a stronger binding 
affinity and is more potent.17 Ligand-free AR in the cytosol is bound to heat-shock 
proteins (Hsp-70 and Hsp-90) that stabilize the receptor and protects it from 
degradation. Androgen binding to the receptor induces a conformational change 
that results in dissociation of the Hsp proteins. Two AR with bound ligand then 




nucleus. Inside the nucleus the complex binds to target genes termed androgen 
response elements (AREs) and initiates transcription of genes regulating growth, 




Effects of androgen deprivation 
The normal prostate gland needs androgens for survival. Androgen withdrawal 
results in loss of secretory function, decreased cell proliferation and a rapid 
reduction in glandular size,18 which is caused by a widespread apoptosis among the 
epithelial cells.14,19 It was for a long time assumed that castration-induced epithelial 
cell death was mediated by decreased AR signalling in the epithelial cells. 
However, recent studies indicate that it is in fact the stroma that regulates the major 
effects observed in the epithelium. Mice that expressed stromal AR but not 
epithelial AR responded similarly to androgen withdrawal as mice expressing AR 
in both stromal and epithelial cells. Mice that lacked AR in the stromal cells did not 
respond to castration at all.19 In addition, the prostate epithelial cell death is 
preceded by a major reduction in blood flow20,21 and by apoptosis of the endothelial 
cells.22 Similarly, testosterone administration results in the complete regeneration of 
the prostate gland, which is preceded by an increase in blood flow and regrowth of 
the vasculature.20,23 Castration-induced prostate involution is therefore partly 








Prostate cancer is one of the major health issues in the Western countries and for no 
other cancer form the incidence increases so quickly. Most likely, the increasing 
number of diagnosed cases originates from a frequent use of PSA as a diagnostic 
tool. Prostate cancer is the most frequently diagnosed cancer form in men in 
Sweden and approximately 9000 new cases are discovered each year. Prostate 
cancer also accounts for the most common cancer related death among men in 
Sweden, and each year about 2300 men die of the disease (Swedish Cancer 
Registry 2007).  
 
The cause of prostate cancer is not known. Its occurrence is strongly related to age, 
and the majority of the patients are between 60 and 70 years when diagnosed.24 




geographic variations in the incidence, and prostate cancer is more common in 
Europe and in USA than in Asia, which points to the importance of lifestyle and 
environmental factors. It has been suggested that isoflavonoids, which are 
constituents of soy, have a protective effect against prostate cancer, which could 
explain the low incidence in Asia. It is also generally considered that lycopenes 
have a protective effect against development of prostate cancer. In contrast, high 
energy intake, high body mass index (BMI) as well as the metabolic syndrome are 
considered risk factors for prostate cancer.25 There is also an ongoing discussion if 
prostatic inflammation may contribute to the development and progression of 
prostate cancer. Some epidemiological studies have shown a significant association 
between prostatitis and prostate cancer26 while others have failed to demonstrate an 
association.27 Hereditary factors account for a relatively small fraction (5-7%) of 
the cases. In 1996, the first susceptible prostate cancer gene was discovered and it 
was named Hereditary prostate cancer 1 (HPC1). However, studies have shown that 
there are only a small fraction of the hereditary cases that are caused by HPC1 and 





The cellular origin of prostate cancer is still controversial. It has been proposed that 
luminal cells are responsible for the tumor-initiating capacity, due to the fact that 
most prostate cancers display luminal characteristics. However, there is now 
increasing evidence that prostate cancer arises from the undifferentiated stem cells 
that are present in the prostate.9 Since the stem cells do not express AR and are 
independent of androgens, their presence is specifically interesting for the 
development of AI disease (see below). 
 
Prostate cancer is a multifocal and heterogeneous disease, where several tumor 
locations are found within the prostate at the time of diagnosis.28 In general, 
prostate tumors are considered to be slowly growing.29 It is estimated that about 
half of the elderly male population have an insignificant, latent prostate cancer but 
the vast majority of them will never suffer from the disease. One problem today is 
to identify progression markers to distinguish indolent tumors from those tumors 
that will progress rapidly and cause the death of the patient.  
 
The progression of prostate epithelial cells into a malignant phenotype is a 
multistep process (fig. 3). In many men, a precursor stadium to prostate cancer can 
be found, so called prostatic intraepithelial neoplasia (PIN). These premalignant 
lesions can develop into malignant tumors, which in the beginning are localized 
within the prostate. Additional genetic alterations result in development of a locally 




surrounding tissue. Prostate cancer preferentially forms metastases to the bones and 
to the lymph nodes. As the normal prostate, prostate cancer is initially AD for 
growth and survival. This feature makes it possible to treat prostate cancer with 
androgen deprivation therapy (ADT). AD tumors respond to castration in a similar 
way as the normal prostate tissue, i.e. a reduction in blood flow and apoptosis of 
endothelial cells30 and of epithelial tumor cells,31,32 which altogether results in 
reduced tumor burden. However, the initial androgen-dependency is generally lost 
during tumor progression and after a certain time an AI tumor relapses. AI tumors 
(or hormone-refractory tumors) are highly aggressive and metastatic and the patient 
survival is generally less than a year.  
 
 
Figure 3: The progression of prostate cancer is a multistep process.  




Diagnosis and pathology 
The common method to diagnose prostate cancer is through rectal palpation or 
transrectal ultrasound together with core biopsies from the prostate. In addition, the 
PSA test is commonly used to assess the risk for prostate cancer. Normal prostate 
tissue prevents PSA to reach the blood. However, in the diseased prostate (i.e. 
prostate cancer and prostatitis), the basement membrane is leaky, resulting in 
increased blood levels of PSA. A normal PSA value is in the range of 0-3 ng/ml. 
However, many men over 50 years have a PSA value between 3 and 10 ng/ml, 
which could be due to prostate cancer, but more often this is due to BPH. 
Unfortunately, the PSA test has low specificity and sensitivity and therefore it is 
not possible due to PSA to differentiate between low and high malignancies. If the 
PSA value is above 100 ng/ml it is generally an indication of widespread metastatic 
disease.25 After confirmed prostate cancer diagnosis, additional investigations with 
regard to metastases are performed, which include radionuclide bone scans to 
detect possible metastatic lesions in the bone. In addition, in relation with 
prostatectomy, regional lymphadenoectomy could be performed to investigate for 
presence of lymph node metastases with subsequent histology. Prostate tumors are 
usually classified according to the TNM system, which makes it possible to study 





Table I: TNM classification of prostate tumors 
T – Primary tumor 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically unapparent, neither palpable nor visible by imaging 
T1a Tumor incidental histologic finding in 5% or less of tissue resected 
T1b Tumor incidental histologic finding in more than 5% of tissue resected 
T1c Tumor identified by needle biopsy 
T2 Tumor confined within the prostate 
T2a Tumor involves half of a lobe or less 
T2b Tumor involves more than half of a lobe but not both lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through the prostatic capsule 
T3a Unilateral extracapsular extension 
T3b Bilateral extracapsular extension 
T3c Tumor invades seminal vesicles 
T4 Tumor is fixed or invades adjacent structures other than the seminal vesicles: 
bladder neck, external sphincter, rectum, levator muscles, or pelvic wall 
  
N – Regional lymph nodes 
NX Regional lymph node cannot be assessed 
N0 No regional lymph node metastases 
N1 Metastases in regional lymph nodes 
  
M – Distant metastases 
MX Distant metastases cannot be assessed 
M0 No distant metastases 




The most common way to obtain tissue specimens from the prostate is with needle 
biopsies through the rectal wall. There is no standard direction on how many 
biopsies that should be sampled and how they should be taken. However, usually 
between 6 and 12 biopsies are taken. The Gleason score33 is the most commonly 
used histological grading system for prostate cancer and it correlates with tumor 
progression.34,35 This method was established in the 1960s and is based on the 
growth pattern of the tumor. The Gleason score is the sum of the most common and 
the most aggressive growth patterns that are graded from 1 to 5, with 1 being the 





Treatment of prostate cancer 
 
Treatment of localized prostate cancer 
Localized prostate cancer is the most commonly diagnosed cancer stage. The 
choice of treatments is active surveillance, radical prostatectomy or radiotherapy 
and is based on the patient’s life expectancy and grade of malignancy. The 
recommendation is that men with a short life expectancy who have early stage 
prostate cancer should be followed by surveillance as first choice.36 Younger 
patients with longer life expectancy or patients with more poorly differentiated 
tumors are offered curative treatment. The most common curative treatment in 
Sweden is removal of the prostate gland with radical prostatectomy. Another 
curative treatment option for localized prostate cancer is radiotherapy.36  
 
 
Treatment of locally advanced prostate cancer 
In patients with extracapsular tumor extension, prostatectomy is not the first option, 
since there can be difficulties to remove the whole tumor. Treatment 
recommendations for locally advanced prostate cancer are instead a combination of 
hormonal therapy and dose-escalating radiotherapy.37 Another option is hormonal 
treatment in the form of anti-androgens or castration therapy (see below).  
 
 
Treatment of metastatic prostate cancer 
Metastatic prostate cancer is treated by ADT. Already in 1941 Huggins and 
coworkers performed their pioneering work on hormonal treatment of advanced 
prostate cancer,38 which was later awarded with the Nobel Prize. Testicular 
androgens can be eliminated by surgical or medical castration. Medical castration 
includes treatment with GnRH analogs that exerts its pharmacological action 
through downregulation of the GnRH receptors present on pituitary gland. This 
results in inhibition of LH and the subsequent testosterone secretions from the 
Leydig cells of the testis. GnRH agonists decrease serum testosterone to castration 
levels after 3-4 weeks. This is preceded by a transient increase in serum 
testosterone, known as the flare period, which could cause worse symptoms for the 
patient.36,39 To avoid the flare period, GnRH antagonists that have direct actions on 
the receptors, have recently been developed.40 Chemical castration can also be 
obtained by administration of estrogens, which results in decreased secretion of LH 
from the hypothalamus via a negative feedback loop. In addition, anti-androgens, 
such as bicalutamide, can be used to block the androgenic effects. Anti-androgens 
have peripheral actions by directly binding and blocking the AR in the prostate 
cancer cells.36,39 
 
About 80% of the patients will have symptomatic relief after ADT.36 Although 




contribute to the decline in mortality rates by delaying death from prostate cancer 
long enough for the patient to die of unrelated causes. From animal experiments 
and clinical trials it has been shown that early initiation of endocrine therapy is 
beneficial, at least in more aggressive cancers, and improves survival.41,42 
Intermittent androgen ablation is a treatment modality that has been introduced into 
the clinic43 but there are no relevant endpoints yet, therefore this should so far be 
considered as experimental.  
 
 
Treatment of AI prostate cancer 
Treatment of AI prostate cancer is only palliative and median patient survival is 
less than a year. Despite the AI nature of the tumor, it is of importance to continue 
with ADT in this stage of disease.44 In addition, a second-line treatment with anti-
androgens can be beneficial for the patient. Treatment with the cytotoxic drug 
docetaxel has been introduced in the clinic and it has been shown to improve 
median survival with a few months.45,46 Prednisone is also used in the treatment of 
AI prostate cancer and it often results in improved well-being. Development of new 
treatment strategies for the AI stage of prostate cancer is of importance and is 
urgently needed. There are several drugs that are in early clinical trials.47 However, 
there are no conclusive results yet and the role of these drugs for treatment of 




Mechanisms of development of AI prostate cancer 
ADT results in a temporarily relief for patients with advanced prostate cancer, but 
will eventually trigger the development of an AI prostate tumor. AI prostate cancer 
is highly aggressive and metastatic and is a major challenge for clinicians. The 
factors that trigger development of AI prostate cancer are currently not known. 
Neither is the point when the molecular alterations that promote AI prostate cancer 
occur. Results from an early study suggested that untreated metastatic tumors 
already contain the alterations needed for recurrence to occur during the pressure of 
ADT.48 However, later studies instead support the theory that ADT trigger the 
molecular alterations that result in development of an AI prostate cancer.49,50 
Recurrent prostate tumors often reexpress AR target genes and AR is observed at 
high frequency in these tumors.51-53 In addition, AI tumors respond to additional 
hormonal manipulations, such as anti-androgens.54 These data suggest that most of 
the recurrent tumors are neither AI nor hormone-refractory, because they continue 
to depend on the AR signaling axis for growth. A more accurate name for 
AI/hormone refractory prostate cancer is therefore “castration-resistant” prostate 
cancer. Transition into androgen-independency is a complex process and despite a 




unknown. Theories to the development of AI prostate cancer includes several AR 
related mechanisms but also mechanisms not related to the AR.  
 
 
AR related mechanisms 
Much attention has been paid to the AR in the development of AI prostate cancer. 
Several mechanisms that serve to activate the AR in absence of androgens have 
been described (fig. 4).  
 
1) Amplification of the AR gene could be one possible mechanism that 
facilitates proliferation of prostate cancer cells in low concentrations of 
androgens. Visakorpi and colleagues reported that AR amplifications are 
increased during ADT,55 which has later been confirmed by others.52,56 
Amplifications have also been observed in bone metastases57 suggesting the 
involvement of AR in the progression of the disease.  
 
2) Point mutations in the steroid binding domain of the AR are another 
mechanism that has been proposed to be of importance in development of AI 
prostate cancer. Mutations result in a promiscuous receptor that allows non-
specific binding of ligands such as estrogens and non-steroidal anti-
androgens. The frequency of AR mutations increases in the AI stage58,59 and 
has also been observed in lymph node and bone metastases.60 Veldscholte et 
al was the first to describe that the LNCaP cell line harbor a AR mutation in 
the ligand-binding domain, thus allowing it to be activated by other ligands 
than androgens.61  
 
3) Hypersensitivity of the AR is another mechanism that can drive the 
proliferation of the prostate cancer cells under low androgen concentrations. 
Gregory et al have reported that this mechanism includes increased 
stabilization and increased nuclear transportation of the AR.62,63  
 
4) Coactivators interact with steroid receptors and enhance their ligand-
dependent transactivation. Some examples of co-activators that have been 
reported to be upregulated in AI prostate cancer are androgen receptor 
associated protein-70 (Ara70), steroid-receptor coactivator-1 (SRC-1), 
transcriptional intermediary factor-2 (TIF-2) and receptor-associated co-
activator-3 (RAC3).62,64,65  
 
5) Androgen deprivation can also result in activation of intracellular signaling 
transduction pathways that can drive the proliferation of the prostate cancer 
cells instead of androgens. These pathways can facilitate activation of the 
AR in absence of androgens or the other alternative is that the AR is 




activated by insulin-like growth factor 1 (IGF-1), the keratinocyte growth 




Figure 4: Mechanisms that have been suggested to be responsible for development of AI prostate 
cancer. Theories include several AR related mechanisms (1-5) but also mechanisms not related to 






6) Development of androgen-independency can also be explained by the 
upregulation of the anti-apoptotic protein Bcl-2 (fig. 4). Bcl-2 is not normally 
expressed by the secretory prostate epithelial cells.67 However, PIN lesions 
frequently express Bcl-2 and increased levels are observed in AI 
specimens.67 Correspondingly, Bcl-2 is upregulated after castration in 
experimental models of prostate cancer68 and inhibition of Bcl-2 resulted in 
delayed progression to androgen-independency.69 Androgen deprivation 
therefore seems to induce signals that results in bypassing of the apoptotic 
response.  
 
7) Prostate tumors are extremely heterogeneous and are probably comprised of 
tumor cells with varying degree of androgen-sensitivity and responsiveness. 
One theory to the development of AI disease is the clonal expansion theory.9 
Coffey and Isaacs have suggested that androgen-independence is due to the 
existence of AI prostate cancer stem cells in the original population of 




AD cells but promote disease progression by activating normally quiescent 
cancer stem cells that would repopulate the tumor with AI cells. Craft et al 
provided further support of the clonal expansion theory and showed that AI 




Interactions between cancer cells and stroma 
Earlier studies by Cunha and coworkers have revealed that the normal prostatic 
stromal cells control the differentiation and development of the normal epithelial 
cells and prostate gland.72 In a similar way, there exists a continuous 
communication between prostate tumor cells and stromal cells. Several biological 
experiments have provided profound evidence that stromal cells play an important 
role in prostate cancer initiation and progression. When non-tumorigenic prostate 
epithelial cell lines were combined with carcinoma-associated fibroblasts (CAFs) 
and implanted as xenografts in immunodeficient mice, tumors were established. 
Tumors were not formed when epithelial cells were injected alone,73-75 showing the 
importance of CAFs in tumor initiation and progression.  
 
The reciprocal interactions between stroma and cancer cells are not only promoting 
growth of the cancer cells. The cancer cells also have a profound influence on the 
stromal cells and the stroma in the vicinity of the tumor is often referred to as 
“reactive stroma”. Experiments addressing the issue of differences between CAFs 
and normal stroma have shown a dramatic difference in tumor forming capacity of 
non-tumorigenic epithelial cells mixed with cancer stroma or normal stroma.75 The 
CAFs promoted a rapid tumor development and progression, while normal stromal 
cells restricted tumor formation. Therefore, during the course of tumor 
development there are profound changes in the stroma, helping the neighbouring 
cancer cells to survive, proliferate and ultimately forming metastases.76  
 
Although androgens are important for maintenance of the normal prostate, they are 
not alone responsible for the regulation. There are several growth factors identified 
that promote interactions and communications between the stromal and epithelial 
compartments. The major prostatic growth factor families include fibroblast growth 
factor (FGF) family, transforming growth factor-β (TGF-β) family, IGF family and 
EGF family. During the course of prostate tumorigenesis many of the normal 
prostate growth factors are altered.77 Exactly how the reactive stromal cells 
influence and regulate the tumorigenic process are not well defined. It is most 
possible that the interactions between the stromal cells and cancer cells differ 
depending on tumor stage. Furthermore, because there are phenotypic differences 
between AD and AI prostate cancer cells it would be interesting to reveal 





Invasion and metastasis 
 
 
The metastatic process 
Primary tumors impair normal tissue function. However, they are only responsible 
for about 10% of the deaths from cancer. The remaining 90% of the cancer deaths 
are caused by metastatic disease.78 Metastases create a great chaos throughout the 
body and therefore they are the most dangerous manifestations of the cancer 
process. For unknown reasons, certain types of tumors never metastasize, while 
others have a high probability to do so. For instance, prostate cancer has a high 
propensity to form metastases to the regional lymph nodes and to the bones.  
 
There are a number of sequential steps that a cancer cell must overcome to succeed 
in the establishment at a new site (fig. 5).79,80 The first step is the detachment of 
single cancer cells from the primary tumor, which involves alterations in the cell 
adhesion profile. To gain access to the vessels for further transportation, the tumor 
cells must break through the basement membrane and path their way through the 
tissue. The invasive properties of tumor cells enable them to move through the 
vessel wall and enter into the circulation, a process called intravasation. Once in the 
circulation, individual cancer cells may travel with the blood or lymph flow to 
distant sites. However, the blood represents a hostile environment for metastasizing 
tumor cells. Hydrodynamic shear forces are present in the blood, which may tear 
the cancer cells apart.78 Experimental studies have shown that survival is greatly 
enhanced if the tumor cells can attract platelets to escort them through the rapid 
blood flow.81 In addition, the most common way for invading cancer cells to move 
through the tissue is as a unit with other cancer cells, thus enhancing their survival 
in the circulation.78 Further, once the tumor cells enter the circulation they will lose 
their anchorage to the underlying stroma. Like normal cells, cancer cells may 
continue to depend on solid substrates for survival. Many cells will therefore 
rapidly die as a result of anoikis (apoptosis that is triggered by detachment from a 
solid substrate).82  
 
The next step for the metastasizing tumor cells that have managed to survive in the 
circulation is to invade the new organ by adhering to the vessel wall and penetrate 
into the surrounding tissue, a process called extravasation. At this point, tumor cells 
use two alternative options. Either they can start proliferate inside the vessel, 
creating a small tumor that pushes on the vessel wall and forces the endothelial 
cells to separate so the tumor can pass. The other option is to invade the endothelial 
wall directly and start proliferating at the new tissue.78 The last step, called 
colonization, is perhaps the most challenging. Many metastasizing tumor cells will 
die once they have arrived at the new site, while others will remain dormant for 




increases those that will eventually expand in size.78 To be able to expand, the 
cancer cell must initiate the formation of new blood vessels, a process called 
angiogenesis. Oxygen and nutrients can only diffuse 1 mm in distance and 
therefore newly formed metastatic foci cannot grow over a size of 1-2 mm3 without 





Figure 5: The metastatic cascade consists of several interrelated, sequential steps. 1) 
Tumorigenesis. 2) Angiogenesis. 3) Detachment of tumor cells, invasion through the tissue and 
intravasation into vessels. 4) Transport through the circulation. Tumor cells must survive the 
hydrodynamic shear forces that are present in the circulation. Survival is greatly enhanced if the 
tumor cells form aggregates with each other or with platelets. 5) Arrival at the new site. For 
prostate cancer this is often the bone. 6) Tumor cells adhere to the vessel wall. 7) Extravasation 
into the new organ parenchyma. 8) Colonization, initiation of angiogenesis and subsequent 




Overall, metastasis is an inefficient process. Of the several millions of tumor cells 
that are seeded into the circulation it is only a small fraction that successfully 
complete all the steps in the metastatic cascade.85,86 Experimental studies have lead 
to the conclusion that the initial steps in the metastatic cascade are completed easily 
for most tumor cells.87,88 However, the last step involving the colonization and 
initiation of angiogenesis at the new site is the rate-limiting. It has been reported 
that three days after intraportally injection of melanoma tumor cells, 83% of the 




Furthermore, 0.02% of the cells persisted and developed into lethal metastases.88 
Similar results have been obtained by others.89 
 
In order to acquire motility and invasiveness, the prostate cancer cells must shed 
many of their epithelial traits and undergo drastic alterations; the epithelial-
mesenchymal transition (EMT). EMT involves changes in cell morphology and 
gene expression pattern, resulting in gain of mesenchymal characteristics. These 
alterations results in extended and elongated cancer cells, allowing for increased 
migratory capacity.90 In addition, there are major changes in the gene expression 
profile during EMT. Expression of E-cadherin and cytokeratins are repressed and 





The seed and soil theory 
It has long been recognized that different cancer types show an organ-specific 
pattern of metastasis. For instance, prostate cancer preferentially forms metastases 
in the bones and metastases from breast cancer are often detected in the brain, 
lungs, bone and liver. Already in 1889, Stephen Paget published a paper that 
described the seed and soil theory.91 He had noticed that certain types of tumor cells 
(the seed) had a high propensity to form metastases in specific organs (the soil) and 
he proposed that this was due to the compatibility between the seed and the soil. 
This idea was challenged in 1920s by James Ewing, who suggested that the patterns 
of blood flow were the primary reason for organ-specific metastasis.79 Today we 
know that both models are valid. Autopsy studies and experimental animal studies 
support the concept that both blood flow and compatibility factors contribute to 
metastatic spread to various organs.79 Together, these studies show that the blood 
flow determine the initial fate of the tumor cells and decide in which organ the 
tumor cells will end up after they have left the primary tumor. However, after the 
cancer cells have arrested in an organ, their ability to grow there is dependent on 
molecular interactions between the cancer cells and the new environment. In 
addition, the new organ must be able to support the cancer cells with the proper 
growth factors. Because chemokines and their receptors are involved in the homing 
of lymphocytes and hematopoietic cells to specific organs, it could be reasoned that 
also cancer cells use chemokines to home to specific organs. In an elegant study by 
Muller and coworkers it was shown that breast cancer cells express the chemokine 
receptors that match the chemokines that are expressed in the organs where these 








It has been observed that metastatic relapse of a tumor can occur decades after 
removal of the primary tumor.93 It has therefore been hypothesized that primary 
tumors shed metastatic cells to the circulation in an early phase of the disease. 
These scattered tumor cells can persist in an inactive state for many years, called 
tumor dormancy.83 Which mechanisms that awake the cancer cells are at present 
unknown. Studies that have modeled tumor dormancy mathematically indicate that 
continuous slow growth is unlikely. Instead a model favoring discontinuous growth 
with periods of quiescence is more likely.94,95 Judah Folkman and colleagues could 
show the existence of preangiogenic metastatic foci in the metastatic niche. In these 
preangiogenic metastases the proliferation was counter balanced by apoptosis, 
resulting in no net increase in tumor volume. When these foci gained the ability to 
vascularize, tumor dormancy ceased and cancer cells started to proliferate.96 
Another possible contributor to tumor dormancy is presence of solitary cancer cells 
at the metastatic site.97 Many cells that arrive in the secondary site fail to initiate 
cell division but remain as quiescent cancer cells. It has been shown that recovered 
solitary mammary carcinoma cells from liver tissue, retained their tumorigenic 
capacity when re-injected into the mammary fat pad of mice.97 These experiments 
show that despite their apparent dormancy at the secondary site, the cells are still 
active. A better understanding of tumor dormancy and the molecular factors that 





Lymphangiogenesis and metastasis 
 
The lymphatic system 
The involvement of the lymphatic system in the metastatic process has been 
intensively investigated over the last years. Many carcinomas, including prostate 
cancer, metastasize to sentinel lymph nodes via the lymphatic vessels. Therefore, 
sign of lymph node metastases is often used as cancer staging in the clinical setting. 
Presence of cancer cells in the lymph nodes are considered as an adverse prognostic 
advent in many carcinomas.98 Thus, removal of the regional lymph nodes is often 
standard procedures, resulting in improved patient survival.  
 
Lymphatic vessels resemble blood vessels, but are generally thinner. The lymphatic 
endothelium has poorly developed junctions and large interendothelial gaps, which 
results in a relatively free import of interstitial fluid. The lymphatic capillaries also 
lack a continuous basement membrane and are devoid of pericytes. These 
properties make lymphatic vessels susceptible for invasion by tumor cells. 




the metastatic process. However, studies have demonstrated formation of new 
lymphatic vessels in tumors, so called lymphangiogenesis,99-101 which is evidence 
of lymphatic vessel activation in cancer. The detailed molecular mechanisms 
behind lymphangiogenesis have been poorly understood but have improved after 
the identification of specific lymphatic growth factors and lymphatic endothelial 
markers. The specific lymphatic endothelial markers include lyve-1,102 
podoplanin103 and prox-1.104  
 
 
Vascular endothelial growth factor C (VEGF-C) 
The first lymphangiogenic growth factor was isolated in 1996 from human prostatic 
carcinoma cells.105 It was found to belong to the group of vascular endothelial 
growth factors (VEGFs) and it was named VEGF-C. Later studies identified 
another family member, VEGF-D106 that also stimulated growth of lymphatic 
vessels. VEGF-C and VEGF-D are glycosylated, secretory proteins and by means 
of proteolytical processing several forms are generated. They mediate their effects 
on lymphatic vessels through the VEGF receptor 3 (VEGFR-3). The expression of 
VEGFR-3 was originally thought to be restricted to lymphatic endothelial cells107 
but further studies revealed that VEGFR-3 was also expressed by a small subset of 
blood vessels.108,109 By proteolytic processing, VEGF-C and VEGF-D gain the 
ability to bind to the VEGFR-2 that is expressed on blood vessels. Thus, they can 
have actions on blood vascular endothelial cells and induce angiogenesis.110 VEGF-
C is definitively one of the main lymphangiogenic growth factor but since its 
discovery others have been identified, including PDGF-BB,111 FGF-2112 and the 
angiopoietin-1 (Ang-1) and -2 (Ang-2).113 
 
The expression of VEGF-C mRNA is upregulated by different factors, including 
PDGF, EGF, TGF-β and also by serum.114 In addition, it has been demonstrated 
that androgen deprivation induces expression of VEGF-C in prostate cancer 
cells.115 In contrast, VEGF-C is not regulated by hypoxia, RAS oncoprotein or 
mutant p53, which are potent inducers of VEGF expression.114 In normal human 
adult tissue, VEGF-C is expressed most prominently in the heart, placenta, ovary 




VEGF-C and its role in lymphatic metastasis 
Today, there is strong evidence that lymphangiogenesis does occur in the presence 
of VEGF-C (fig. 6). VEGF-C can induce hyperplasia of preexisting lymphatic 
vessels117 and can also stimulate the proliferation of newly formed lymphatic 
vessels.118 Overexpression of VEGF-C in transgenic and xenograft models of 
human cancer induced lymphangiogenesis around the tumors and enhanced 




VEGF-C is upregulated in many types of human malignancies and is also related to 
the appearance of lymph node metastases.123-126 Previous to our publication (paper 
I), Tsurusaki et al reported on elevated mRNA levels in tumors from patients with 
lymph node metastases in comparison to tumors from patients without lymph node 
metastases.127 Similarly, expression of VEGFR-3 by lymphatic endothelial cells has 
been shown to be associated with lymph node metastasis in prostate cancer.128 
 
 
Figure 6: Lymphangiogenic growth factors (VEGF-C, VEGF-D, PDGF-BB, Ang-1, Ang-2, 
FGF-2) are secreted from the tumor cells and induce the formation of new lymphatic vessels. 
VEGF-C/D is the most studied lymphangiogenic growth factors and they mediate their effects via 
VEGFR-3 that is expressed on the lymphatic endothelial cells. Increased lymphatic vessel density 
in tumors is associated with presence of regional lymph node metastases. Both peritumoral and 
intratumoral lymphatic vessels have been observed in tumors but there are doubts if the 
intratumoral lymphatic vessels are functional. 
 
 
More recently, is has been observed that lymphangiogenesis not only occur in the 
vicinity of the primary tumor but also in the sentinel lymph nodes.129,130 Notably, 
lymph node lymphangiogenesis was observed even before the arrival of tumor 
cells, which indicate that the primary tumor starts to prepare the metastatic site 
prior to the dissemination of tumor cells.131,132 Although metastasis to distant 
organs most likely occurs via the hematogeneous system, it might require the initial 
spread of tumor cells to the regional lymph nodes, from where the cancer cells can 
spread further. This is supported by a study where metastasis to distant organs was 




human lymph nodes infiltrated with metastatic melanoma cells also exhibited 
lymphatic vessel growth, indicating that lymph node lymphangiogenesis can be a 




Cell adhesion molecules in cancer 
 
Cell adhesion molecules (CAMs) 
Cell adhesion molecules (CAMs) are present between cells and between cells and 
the extracellular matrix (ECM) and they constitute key components that maintain 
the normal structure, integrity and function of cells and tissues.134 Epithelial cells 
connect to each other and to the ECM by adherens junction, desmosomes and cell-
matrix adhesion complexes (fig. 7). The adherens junctions, consisting of the 
cadherin class of CAM, connect to the cytoskeletal actin filaments, which creates 
an adhesion belt around the cell. The desmosomes on the other hand, connect 
adjacent cells via the intermediate filaments. Cell-cell adhesion is mainly mediated 
via the cadherins and cell-matrix adhesion is mainly mediated via the integrins. In 
addition, there are also adhesive proteins that are part of the tight junctions. Tight 
junction proteins maintain the polarity of epithelial cells by separating the apical 
side from the basolateral side of the cells. During cancer development, there are 
major rearrangements and alterations in the CAMs, resulting in increased tumor 
cell motility.    
 
 
Figure 7: Epithelial cells are connected to each other via adherens junctions and desmosomes. 
The adherens junctions provide cell-cell adhesion via the cadherins, which is connected to the 
actin cytoskeleton that form an adhesion belt around the cell. The desmosomes connect to the 
intermediate filaments. Tight junctions separate the apical side from the basolateral side, keeping 
the epithelial cells in a polarized state. Cell-matrix adhesion is mainly mediated via integrins. 






Structure and function 
The cadherins are a superfamily of CAMs that mediate adhesions between cells in 
the presence of extracellular calcium. Different cadherins are differentially 
expressed during embryonic development, indicating distinct functions in cell 
adhesion. The cadherins are composed of a large extracellular domain that binds 
with homophilic bonds to cadherins on neighboring cells, resulting in stable forces 
between adjacent cells. Cadherins also have one transmembrane segment and a 
highly conserved intracellular domain. The cytoplasmic part of the cadherins is 
anchored to the actin cytoskeleton via a second group of proteins called the 
catenins.134 The linkage to the cytoskeleton is crucial for the cell adhesion function 
of the cadherins. There are three major catenins; α-, β-, and γ-catenin that regulate 
the function of the cadherins.135 The most extensively studied cadherins are the 
three classical cadherins E-cadherin, N-cadherin and P-cadherin.  
 
E-cadherin and cancer 
E-cadherin maintains the integrity and polarity of normal epithelial tissue. Over the 
last years, several investigations on the functional role of E-cadherin have been 
performed. Inhibition of the function of E-cadherin with blocking antibodies 
resulted in disruption of cell contacts in vitro and induction of a more motile 
phenotype.136-138 Conversely, forced expression of E-cadherin in cancer cells 
impaired the invasive capacity.137,139 These results clearly demonstrated a critical 
role for E-cadherin in tumor invasion. Furthermore, using the Rip1Tag2 transgenic 
model of pancreatic cancer, Perl et al could establish a casual role between loss of 
E-cadherin and transition from adenoma to carcinoma.140 Therefore, loss of E-
cadherin results in disruption of the tight contacts that exist between adjacent 
epithelial cells allowing single metastatic cells to escape from the primary tumor. In 
most cases, loss of E-cadherin is due to transcriptional repression by 
hypermethylation or chromatin rearrangements in the promoter region.141-144 Recent 
reports have also highlighted the role of snail, slug, twist and ZEB1 in silencing of 
the E-cadherin gene.145-148 These transcription factors act as repressors of E-
cadherin gene expression, and thus inducing the metastatic phenotype. In addition, 
loss of E-cadherin can also be a consequence of mutations of the E-cadherin gene149 
or aberrant tyrosine phosphorylation of E-cadherin and associated proteins by 
receptor tyrosine kinases,150,151 which result in disruption of E-cadherin mediated 
adhesion.  
 
Reduction in E-cadherin not only results in decreased cell adhesiveness that is 
important for the first step in the metastatic cascade. It also affects signaling 
transduction pathways that can influence later steps in the metastatic cascade.152,153 
A critical intracellular event resulting from loss of E-cadherin is the accumulation 




cadherin complex, β-catenin also function as a transcription factor and participates 
in Wnt-mediated signaling transduction.153 Non-sequestered, free β-catenin is 
rapidly phosphorylated by glycogen synthase kinase 3β (GSK-3β) in the 
adenomatous polyposis coli (APC)/GSK-3β/axin complex and subsequently 
degraded by the ubiquitin-proteasome pathway. If the tumor suppressor APC is 
non-functional or if GSK-3β activity is blocked by activated Wnt-signaling, β-
catenin accumulates at high levels in the cytosol. It is thereafter translocated to the 
nucleus, where it binds to members of the TCF/LEF transcription factors and 
modulates the transcription of target genes, including c-myc, cyclin D1, fibronectin 
and matrilysin.154-157 There are also studies demonstrating that β-catenin can bind 
AR in prostate cancer cells and thus regulate transcription of androgen-regulated 
genes.158,159  
 
E-cadherin has been extensively studied in prostate cancer. E-cadherin expression 
is inversely related to prostate tumor grade160-165 and to adverse clinicopathological 
features.165 E-cadherin is reduced in high grade tumors with positive surgical 
margins166 and is downregulated in lymph node metastases 167 and bone 
metastases168 from prostate cancer. Interestingly, there are also studies that have 
demonstrated the re-expression of E-cadherin in metastatic cancer cells,169,170 where 
the primary tumor was E-cadherin negative. This might imply that loss of E-
cadherin is a transient event that can be influenced by the surrounding environment. 
Cumulative evidence suggest that E-cadherin act as a broad suppressor of growth 
and invasion of epithelial cancer and its functional elimination in tumors represents 
a key step in the acquisition of the invasive and metastatic phenotype.  
 
The cadherin switch 
The loss of E-cadherin in cancer is most often accompanied by gain of another 
CAM, namely N-cadherin. This “cadherin switching” plays an essential role for the 
metastatic process. In normal tissue, N-cadherin is extensively expressed in the 
nervous system but can also be found in the vascular system and in the 
myocardium.171,172 Although N-cadherin forms the typical homophilic interactions 
to other N-cadherin expressing cells, heterotypic interactions to other molecules 
have also been described.173 Experimental studies demonstrate that N-cadherin 
induces a scattered cell morphology and increases the motility of tumor cells.174-177 
In addition, N-cadherin promotes invasiveness and metastasis in several animal 
models of cancer.174,178  
 
The most possible mechanism by which N-cadherin renders tumor cells more 
motile is through the homophilic adhesion to other cells. Firstly, N-cadherin 
mediates a dynamic cell adhesion179 resulting in weaker interactions between 
adjacent cells than E-cadherin.180 Thus, it allows the dissociation of single cells 




and N-cadherin expressing tissue, such as the stroma and vasculature facilitate the 
transit through the tissue and survival of tumor cells in distant organs. It has for 
instance been demonstrated that N-cadherin promoted the transmigration of 
melanoma cells through the vasculature.181,182 It is largely unknown how N-
cadherin participates in the dynamic remodeling of the cytoskeleton that is required 
for cell motility. Studies have demonstrated that the invasive capacity of N-
cadherin is in part due to a functional interaction with the FGF receptor 1 (FGFR-
1). The interaction between FGFR-1 and N-cadherin causes sustained signaling of 
the MAPK-ERK signaling pathway, which ultimately leads to increased 
transcriptional activation of the proinvasive enzyme matrix metalloproteinase 9 
(MMP-9).183 In addition to the promigratory role, it has been demonstrated that N-
cadherin promotes survival of carcinoma cells, through inactivation of the pro-
apoptotic molecule Bad and activation of the anti-apoptotic Bcl-2.175,184 It has also 
been reported that N-cadherin can be involved in angiogenesis. The extracellular 
domain of N-cadherin can be cleaved by plasmin resulting in a soluble fragment of 
90 kDa. This fragment stimulates angiogenesis and has been shown to be elevated 
in serum of prostate cancer patients.185,186 It has been suggested that N-cadherin 
expression is dominant over E-cadherin expression because experimental studies 
have shown that the proinvasive action of N-cadherin persisted even in the presence 
of E-cadherin.174,187  
 
In prostate cancer, the cadherin switch has been observed in more aggressive 
prostate cancer cell lines.177,188 In addition, N-cadherin has been observed in poorly 
differentiated areas of prostate cancer and its expression correlated to Gleason 
score.188-190 It has also been demonstrated that expression of N-cadherin was 
associated with seminal vesicle invasion, pelvic lymph node infiltration and shorter 




The integrins are a diverse family of CAMs that are expressed in all cell types and 
they play a crucial role in cell survival, proliferation, migration, gene expression 
and activation of growth factor receptors. They mediate interactions between cells 
and the ECM by serving as receptors for various molecules, such as fibronectin, 
vitronectin, collagen and laminin. The integrins are heterodimers and are formed by 
a non-covalently link between one α-subunit and one β-subunit. At this time, there 
are 18 α-subunits and 9 β-subunits known to be expressed, which can assembly into 
24 different integrin heterodimers with distinct functions.191 The functional 
specificity is determined by each pairing and the cell type that expresses the 
integrin. Each integrin generally consists of a large extracellular domain, a 
transmembrane part and a short cytoplasmic tail, which are involved in the 
signaling system of the cell. They possess the ability to use bidirectional signaling. 




regulate the adhesiveness towards ECM; called inside-out signaling. In addition, in 
response to ligand binding to the outside they can transduce signals from the 
extracellular domain to the inside of the cell; called outside-in signaling.192,193  
During prostate cancer development and progression there are major changes in the 
expression profile of the integrins, both in their levels and distribution.194 These 
changes enable tumor cells to convert from a stationary to a mobile phenotype. 
Several reports show a deregulated integrin expression in the progression of 
prostate cancer, where most α and β subunits are decreased.191,194 Some integrin 
subunits, such as α2 are also elevated in metastatic lesions in comparison to the 
primary tumors, indicating a role in facilitating tumor cell migration and 
metastasis.195 Bone is a frequently involved metastatic site in prostate cancer and 
several studies have implicated the importance of the subunit αv in combination 
with β3 for the attachment and survival of prostate cancer cells in the bones.196,197 
αvβ3 is upregulated in prostate cancer198 and prostate cancer cells isolated from 
bone metastases express αvβ3 integrin receptors. αvβ3 could also promote 





Role of MMPs for metastasis 
MMPs have long been recognized as important players for the metastatic process. 
The MMPs comprise a family of zinc-dependent endopeptidases that are 
synthesized as inactive zymogens and usually become activated outside the cell by 
means of other MMPs or by serine proteinases. The MMPs can cleave almost all 
components of the extracellular matrix that constraint the movement of the tumor 
cells. Through the controlled cleavage of the ECM components the MMPs assist 
cancer cells in the invasive process by creating a passage for the tumor cells to 
nearby vessels. In addition, the modulation of the ECM results in release of 
sequestered growth factors, which further stimulates the invasive process. 
Moreover, the MMPs may activate latent forms of growth factors and proenzymes 
through proteolytic cleavage.200 Notably, in many cases the MMPs are found to be 
synthesized by recruited stromal cells, such as fibroblasts, macrophages and mast 
cells, rather than by the tumor cells themselves.201 Several soluble factors that are 
secreted from the cancer cells have been shown to induce the expression of MMPs 
from fibroblasts in vitro, for example EMMPRIN (extracellular matrix 
metalloproteinase inducer).202 The activity of the MMPs is tightly regulated by 
endogenous inhibitors, including the tissue inhibitors of metalloproteinases 
(TIMPs) and α2-macroglobulin.200 
 
The contribution of the MMPs to tumor progression has been shown in several 
animal models, where overexpression results in a more invasive phenotype. 




aggressiveness.203 Clinical data also strongly support a role for the MMPs in 
progression of human cancer. The levels of MMPs are upregulated in nearly every 
human cancer, which correlates with advanced tumor stage, increased invasion and 
metastasis and shortened patient survival.200 Due to MMPs broad involvement in 
the metastatic process, pharmaceutical inhibitors have been tested in clinical trials 
but so far without success, 204 most probably due to the complexity of the MMPs. 
 
MMP-2 and MMP-9 are of specific interest for the metastatic process, since they 
are known to degrade collagen IV that is an important constituent of the basement 
membrane. In prostate cancer, MMP-2 and MMP-9 are elevated and the 
expressions are related to advanced non-organ confined disease.205,206 Another 
MMP that has been strongly implicated in the metastatic process is the membrane-
type 1 (MT1)-MMP. This protease promotes invasion and metastasis of 
experimental prostate cancer207 and is highly expressed in human prostate cancer 
bone metastases.208   
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Prostate cancer is the most common type of cancer among men in Sweden and 
there are approximately 9000 new cases each year. Many of these men will have an 
insignificant cancer, which will not harm them. However, approximately 25% of 
the tumors are aggressive and metastasize to lymph nodes and to the bones. 
Initially, ADT is successful in reducing tumor volume, but over time, a highly 
metastatic AI tumor relapses, which will eventually cause the death of the patient. 
To improve treatment for patients with AI prostate cancer, further studies of 
molecular and cellular characteristics in this stage are needed. The general purpose 
of the present thesis was to investigate invasive and metastatic properties of 
advanced prostate cancer, with a special emphasis on the AI stage. With the 





• To investigate the expression pattern of the lymphangiogenic factor VEGF-C 
and its receptor VEGFR-3 in human prostate cancer and the possible 
association of these factors to lymph node metastasis. 
 
• To evaluate if LNCaP-19 is a relevant model for studies on the invasive 
properties of AI prostate cancer.  
 
• To investigate molecular and cellular alterations that are specifically related 
to transition into androgen-independency, with emphasis on characteristics 
related to the invasive and metastatic process.  
 
• To develop a technique to follow intraprostatic tumor growth with magnetic 
resonance imaging (MRI) in mice.  
 
• To investigate how different microenvironments and androgen levels 
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Formalin-fixed and paraffin-embedded tissues were obtained from patients with 
prostate cancer from the Department of Urology, Sahlgrenska University Hospital, 
Gothenburg, Sweden. The studies were conducted with ethical approval of the local 
research ethical committee.  
 
 
Materials obtained by prostatectomy (paper I)  
Prostate cancer specimens were obtained from 22 patients by open prostatectomy, 
based on the assumption that the patients had localized prostate cancer. As routine, 
regional lymph nodes were resected and judged for presence of metastases. The 
patients had not received preoperative neoadjuvant hormonal therapy. Eleven 
patients were positive for metastases in regional lymph nodes and eleven had no 
known metastases. Mean Gleason score for patients without and with lymph node 
metastases was 6.6 (range 6-7) and 7.6 (range 7-9) respectively.  
 
 
Materials obtained by transurethral resection of the prostate (TURP) 
(paper IV)  
Specimens were obtained from 53 patients that underwent transurethral resection of 
the prostate (TURP). 28 patients had TURP-diagnosed untreated prostate cancer in 
stage T1b and 25 patients had recurrent castration-resistant prostate cancer after 
ADT. T1b tumors are clinically unapparent tumors that are not palpable and where 
the tumor finding involves more than 5% of the resected tissue. In the hormone 
naïve T1b group mean age was 77 years (range 60-90) and mean Gleason score was 
6.6 (range 5-9). In the castration-resistant group, mean age was 79 years (range 65-
88) and mean Gleason score was 9.1 (range 7-10).  
 
 
Materials obtained through prostate biopsies (paper IV)  
Prostate biopsies from 11 patients were obtained sequentially during prostate 
cancer progression and PSA was measured in serum at the same time points. 
Biopsy 1: sampled at the time of prostate cancer diagnosis prior to ADT. Biopsy 2: 
sampled approximately three months after initiation of ADT. Biopsy 3: sampled 
when the tumor relapsed as indicated by a rise in PSA or when the patient had 
symptomatic progression. Mean Gleason scores in the groups were 7.4, 7.5 and 8.2 
respectively. Mean age at the time of diagnosis was 73 years (range 63-81). 
MATERIALS AND METHODS 
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Cell lines and cell culture 
The human prostate cancer cell line LNCaP was obtained from American Type 
Culture Collection (Manassas, VA, USA). LNCaP is an AD cell line once 
established from a lymph node metastasis from a castration-resistant patient. 
LNCaP expresses the AR and secretes PSA and is one of the most common AD cell 
lines used in prostate cancer research. LNCaP has a mutated AR that can bind 
androgens in addition to other steroid hormones.61  
 
To be able to study transition into androgen-independency we developed an AI cell 
line, LNCaP-19, from the LNCaP cells.209 LNCaP-19 was developed in vitro by 
culturing the normal LNCaP cells in medium containing steroid-depleted serum. 
LNCaP-19 expresses the AR, although at lower levels than LNCaP, and has an 
increased angiogenesis compared to its parental cell line. It establishes tumors in 
castrated animal, indicating true AI growth. In paper IV, we also included the AI 
cell line PC-3. PC-3 was established from a human prostate cancer bone 
metastases210 and PC-3 is a dedifferentiated and highly aggressive cell line that 
lacks AR and expression of PSA.   
 
Cells were routinely maintained in RPMI 1640 (PAA Laboratories, Linz, Austria), 
modified according to the manufacturer’s protocol and supplemented with 
antibiotics and 10% fetal bovine serum (FBS) (GibcoTM, Invitrogen LTd., Paisley, 
UK) for LNCaP and PC-3 and 10% dextran-charcoal treated FBS (DCC-





Animals and tumor cell implantation 
Male athymic BALB/c nude mice were used for subcutaneous and orthotopic 
implantations of tumor cells (paper II-IV). BALB/c nude mice are immunodeficient 
and lack T-lymphocytes, which thereby allows establishment of human tumors. For 
the metastasis experiment (paper IV) we used SCID CB17 mice. SCID mice are 
more immune compromised than BALB/c nude mice and they lack both T- and B-
lymphocytes. Tumor cells are therefore more tumorigenic and have a higher 
propensity to establish metastases after implantation in SCID mice. Mice were at 
least 7 weeks old when the experiments started. Mice turn sexually mature at this 
age and this is therefore a common starting point for studies on prostate cancer. The 
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Subcutaneous implantation of cells (paper II-IV)  
Two million tumor cells, suspended in equal volumes of culture medium and 
matrigel (BD Bioscience, Bedford, MA, USA), were inoculated subcutaneously in 
the flank of the mice. Matrigel is a solubilized basement membrane preparation 
extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, which is a 
tumor that is rich in ECM proteins. The major components are laminin, collagen 
IV, heparan sulphate proteoglycans, entactin and nidogen and various growth 
factors are also present. The use of Matrigel facilitates the establishment of human 
cancer cell lines as xenografts in mice. Prior to cell injection, castration or sham-
operation was performed via a scrotal incision under anaesthesia. Tumors were 
measured with a caliper and the formula (length x width2 x 0.5) was used to 
calculate tumor volume. The experiment was ended after a certain time point or 
when the tumors reached a volume of maximum 1300 mm3.  
 
 
Orthotopic implantation of cells (paper III and IV) 
Mice were anesthesized and a transversal incision was performed in the lower 
abdomen. In experiments involving castrated mice, castration was performed prior 
to cell injection via the abdominal incision. One million cells suspended in matrigel 
(BD Bioscience) were injected into the dorsolateral lobe of the prostate using a 30-
gauge needle. The abdominal incision was closed with interrupted sutures. The 
dorsolateral lobe was chosen because of its resemblances with the peripheral zone 
in humans, which is the most common origin of human prostate cancer. The 
experiments were ended after 9 weeks. The metastasis experiment in SCID mice 
was ended after 15 weeks. Mice were examined for metastases and primary tumors 
and macroscopic lymph node metastasis were collected.  
 
 
Treatment with testosterone (paper III)  
Three weeks after orthotopic LNCaP-19 tumor cell implantation, castrated mice 
were divided into two groups with comparable tumor volumes (mean tumor volume 
= 62 mm3). One group received testosterone, 10 mg/kg (Sustanon® 250, Organon, 
Oss, The Netherlands), with subcutaneous injections every other day. Treatment 
proceeded until week 9 when the experiment was concluded. Castrated and intact 
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Magnetic resonance imaging (MRI) 
In paper III, the technique of MRI was applied to monitor orthotopic tumor growth 
over time in the mice. We used a 7.05 T Bruker BioSpec MR system (Bruker 
BioSpin, Ettlingen, Germany) equipped with a 72 mm volume coil for transmission 
of radiofrequency for MRI. A linear 4-element phased array coil with 16 mm 
circular elements served as a receive coil. Twenty coronal slices through the normal 
prostate/prostate tumor were acquired with a multi-slice, multi-echo sequence. The 
scan time was 13 minutes per data set. Regions of interest were defined manually in 
each slice using the ParaVision program. Calculation of tissue volumes was 




In vitro studies 
 
Anchorage-independent growth (paper II) 
Anchorage-independent growth is a hallmark of malignant tumor cells. Thus, 
cancer cells can grow and survive without attaching themselves to the underlying 
matrix. It has been suggested that cell-cell adhesion molecules or integrins are 
involved in anchorage-independent growth. In this study, anchorage-independent 
growth of the cancer cells was assessed by colony formation in soft agar. Fifty 
thousand cancer cells in serum free medium were suspended with an equal volume 
of 2% low-melt agarose (A-9045, Sigma-Aldrich, St Louis, MO) and seeded in 
Petri dishes, pre-coated with 1% standard agarose (162-0100, Bio-Rad 
Laboratories, CA). Colony formation ability was investigated in triplicates in 
culture medium containing 10% DCC-FBS and in culture medium containing 10% 
DCC-FBS plus 0.1 nM R1881 (NEN Life Science Products, Inc., Boston, MA). 
Colonies, defined as cell clusters consisting of more than 10 cells, were counted 
after 28 days under a light microscope. The experiment was repeated three times. 
 
 
Cell migration (paper II) 
Ability to migrate is another property that is essential for cancer cells to be able to 
invade surrounding tissue and metastasize. Migration assays were performed using 
Transwell polycarbonate membranes with 12 µm pore size (3403, Corning, Life 
Sciences, Acton, MA). Eighty-five thousand cancer cells in culture medium 
containing 1% DCC-FBS were seeded in the inserts in duplicates. Culture medium 
containing 10% DCC-FBS was added to the lower chambers and used as 
chemoattractant. To investigate possible androgenic effects on migration, wells 
with addition of 0.1 nM R1881 in both upper and lower chamber were also 
included. Cells were incubated for 24 hours. Migrating cells on the lower side of 
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the membrane were fixed in methanol and stained with hematoxylin. Cells were 
counted in 10 objective fields, under a light microscope, at 200x magnification. The 
experiment was repeated three times.   
 
 
Cell adhesion assay (paper II) 
Fibronectin and vitronectin are two of the most common components of the ECM. 
Migrating cancer cells form transient attachments to these structures when they 
move through the tissue. The adhesion is often mediated via integrins, which are 
expressed on the surface of the tumor cells. Cell culture plates with 96 wells, were 
coated with fibronectin (10 µg/ml) or vitronectin (3 µg/ml) (Sigma-Aldrich, St 
Louis, MO). Unspecific binding was blocked with 1% bovine serum albumin 
(BSA) (Sigma-Aldrich, St Louis, MO). Cancer cells were seeded in triplicates in 
serum free culture medium. To investigate transient attachments cells were only 
allowed to adhere for two hours, which would simulate tumor cell arrival at a new 
site or migration through the tissue. Adherent cells were fixed with 95% ethanol 
and stained with crystal violet. Dye was extracted with Triton-100 over night and 
the absorbance was read at 550 nm. Background levels of cell adhesion were 
determined in wells coated with BSA alone and these values were subtracted from 
values obtained for vitronectin and fibronectin. The experiment was repeated three 
times.    
 
 
Cell culture for RNA preparation (paper II and IV) 
For RNA analyses, cells were cultured in 10% DCC-FBS, without or with addition 
of the synthetic androgen R1881 in different concentrations (0.1 nM and 1 nM). 
After a certain time (see specific papers), cells were trypsinized and RNA was 






RNA preparation (paper II-IV) 
Total RNA from cells and tumor tissue was prepared with TRIzol solution (paper 
II) (Invitrogen Ltd.) or by using the RNeasy mini kit (paper IV) (Qiagen Gmbh, 
Hilden, Germany) according to the manufacturer’s recommendations.  
 
Preparation of RNA for the microarray analysis (paper III) was performed by 
combining the TRIzol method with the RNeasy mini kit. The combination of these 
methods results in low degradation of the RNA and usually results in very pure 
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RNA of good quality that can be used for microarrays. Another advantage is that 
the RNA does not need to be DNase treated, which is not recommended when the 
RNA will be used for microarray experiments. Tumor tissues were homogenized in 
TRIzol reagent according to the manufacturer`s protocol. Chloroform was added 
and after a centrifugation step, the aqueous phase was collected and transferred 
onto a mini prep column from the RNeasy mini kit and the subsequent steps were 
according to Qiagen’s protocol. RNA quality and concentration were measured 
using a bioanalyzer (Agilent 2100, Agilent Technologies Inc., Santa Clara, CA, 
USA) and nanodrop (Thermo Scientific NanoDrop, Saveen Werner, Limhamn, 
Sweden) respectively.  
 
 
cDNA synthesis (paper II and IV) 
Total RNA was reversely transcribed by the M-MLV enzyme into cDNA by using 
oligo dT (paper II) or random hexamers (IV). 18S was used as an endogenous 
control in the real-time reactions in paper IV and therefore random hexamers were 
used because these primers convert both messenger RNA (mRNA) and ribosomal 




Polymerase chain reaction (PCR) (paper II and IV) 
In paper II, PCR reactions were performed on a conventional PCR apparatus. For 
the PCR reactions, cDNA was mixed with PCR buffer (1X), MgCl2 (1.5 mM), 
deoxynucleotides (200 µM of each), primers (0.4 µM of each primer) and Taq 
polymerase (1.67 U). For specific details regarding primer sequences, number of 
cycles and annealing temperatures see paper II. GAPDH was used as an internal 
control. PCR products were electrophorezed on a 2% agarose gel containing 
ethidium bromide. Primers were purchased from CyberGene AB (Huddinge, 
Sweden) and other chemicals were from Promega (Madison, WI, USA).  
 
In paper IV, real-time PCR was performed with the ABI Prism 7500 Fast Sequence 
Detector (Applied Biosystems, Applera Corporation, Foster City, CA, USA). PCR 
primers and TaqMan MGB probes were purchased as TaqMan Gene expression 
Assays (Applied Biosystems). PCR parameters were according to the 
manufacturer’s protocol and the ΔΔCt method was used for relative mRNA 
quantification. PCR reactions for target genes and 18S endogenous control were 
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Microarray experiment and data analysis (paper III) 
Gene expression in the LNCaP-19 tumors was evaluated using the Human Gene 1.0 
ST from Affymetrix Inc. (Santa Clara, CA, USA) according to the manufacturer’s 
protocol. Three groups of LNCaP-19 tumors were included as follows: 1: 
subcutaneous tumors from intact mice (sc intact), 2: orthotopic tumors from intact 
mice (ort intact) and 3: orthotopic tumors from castrated mice (ort castrated). Two 
comparisons were made; 1) “ort intact” versus “sc intact” and 2) “ort intact” versus 
“ort castrated”. 
 
Data was normalized using the robust multi-array analysis (RMA) method. Probes 
that displayed signal intensity below 50 in all samples were removed from further 
analysis. Data was log 2 transformed and a SAM analysis was performed to 
identify differentially expressed genes between groups. The false discovery rate 
was set at 5% and a fold change of two or above was considered to be a change in 
gene expression. Gene ontology analysis was performed on differentially expressed 
genes using the Database for Annotation, Visualization and Integrated Discover 






Protein preparation (paper II and IV) 
Total protein was prepared by homogenization in lysis buffer consisting of PBS 
(pH 7.5), 0.15 M NaCl, 0.25% Tween 20 and protease inhibitors (1X, Complete™ 
Mini, Roche Diagnostics, Mannheim, Germany). Samples were sonicated, 
centrifuged and the supernatants were collected. Protein concentrations were 
measured using the BCA protein assay kit (Pierce, Rockford, IL) according to the 
manufacturer’s protocol.  
 
 
Western blot (paper II and IV) 
Fifty microgram of reduced protein was loaded on a 4-12% Bis-Tris gradient gel 
and electrophoresis was performed using MOPS (Invitrogen, Carlsbad, CA, USA) 
as running buffer. Fractionated proteins were electroblotted onto a 
polyvinyldifluoride (PVDF) membrane (Hybond-P, GE Healthcare, 
Buckinghamshire, England). Membranes were blocked in 5% dry milk and 
subsequently incubated with primary antibodies over night at 4 °C. Details 
regarding primary antibodies and concentrations can be found in the specific 
papers. Membranes were incubated with a peroxidase labelled secondary antibody 
and immunoreactions were detected using the ECL™ Western blotting detection 
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system (GE Healthcare). As an internal control, actin (1/5000, A2066, Sigma-
Aldrich, St Louis, MO, USA) was used. The positive controls used can be found in 
the specific papers.  
 
 
Immunohistochemistry (paper I-IV) 
Tissue sections were deparaffinized and rehydrated and sections were heated in 
antigen unmasking solution (Vector Laboratories, Inc., Burlingame, CA, USA) for 
antigen retrieval. Endogenous peroxidase was quenched in 0.3% hydrogen peroxide 
in methanol. Immunohistochemistry was performed using the Vectastain ABC kit 
(Vector Laboratories, Inc.). Sections were incubated with primary antibodies over 
night at 4 ºC. For antibodies and concentrations see the specific papers. The biotin 
streptavidin complex was visualized by using Nova Red substrate (paper I) or DAB 
(paper II-IV) and sections were counterstained with Mayer’s hematoxylin and 
mounted. Negative controls were performed by omitting primary antibodies.  
 
 
Evaluation of immunostaining (paper I-IV) 
The VEGF-C, VEGFR-3 (paper I) and E-cadherin staining (paper IV) were 
evaluated by means of a semi-quantitative scoring system for staining intensity and 
proportion of positive cells. Intensity and proportion of positive cells were judged 
between 0 and 3 and the total score for each slide were then obtained by 
multiplying these scores. The intensity was scored as 0 = no detectable signal; 1 = 
weak staining; 2 = moderate staining; 3 = strong staining. The proportion of 
positive cells were scored as 0 = no positive cells; 1 = <1/3 positive cells; 2 = 1/3-
2/3 positive cells; 3 = >2/3 positive cells. For the N-cadherin staining (paper IV), 
there was no large variation in staining intensity between tumors and therefore 
intensity was not taken into consideration. Proportion of positive cells was scored 
as 0 = no positive cells; 1 = <25% positive cells; 2 = 25-50% positive cells; 3 = 50-
75% positive cells; 4 = >75% positive cells. Sections were evaluated in a blinded 
fashion at 200 x magnification. 
 
Microvessel density (MVD) was evaluated with CD34 immunostaining. In paper 
III, blood vessels were counted at 200 x magnification in five representative fields 
in each tumor section. In paper II, number of vessels containing tumor cells was 
counted at 400 x magnification in 10 randomly chosen fields in each section. 
Percent invasivity was defined as number of vessels containing tumor cells divided 
with total number of vessels with a visible lumen. A blood vessel was defined as 
any immunostained endothelial cell or endothelial cell cluster, separated from 
adjacent vessels, according to Weidner et al.211  
 
 




The Mann-Whitney U test was used to analyze differences between independent 
groups. The correlations between the N-cadherin/VEGF-C/VEGFR-3 score and the 
Gleason score in the tumors were analyzed by using the Spearman’s rank 
correlation test. Comparisons of proportion of positive N-cadherin cases between 
the hormone naïve and castration-resistant group and between tumors from patients 
with metastases and without metastases were analyzed with Fishers chi-square test. 
Wilcoxon signed rank test was used to analyze differences between dependent 
groups, i.e. differences in N-cadherin and E-cadherin staining between biopsies 
collected from prostate cancer patients during tumor progression. A P-value <0.05 
was considered statistically significant. Statistical analysis was performed with the 
statistical program SPSS for Windows.  
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Recent studies have indicated that the lymphangiogenic growth factor VEGF-C 
promotes lymph node metastasis.120-122 In this work, we investigated the expression 
patterns of VEGF-C and its receptor VEGFR-3 in human prostate cancer specimens 
and their possible association with lymph node metastasis.  
 
Expression of VEGF-C and VEGFR-3 was evaluated with immunohistochemistry 
by using a semi-quantitative scoring system, combining the staining intensity and 
proportion of positive cells. Benign prostate epithelial cells were either negative or 
showed a weak, scattered staining pattern for VEGF-C. In contrast, VEGF-C was 
expressed by a majority of the tumor cells but with different intensities. Tumors 
from patients with lymph node metastases had a significantly higher score than 
tumors from patients without metastases. Spearman’s rank correlation test showed 
no significant correlation between the VEGF-C score and the Gleason score. Our 
results were in accordance with a previous report by Tsurusaki et al, showing 
elevated mRNA levels of VEGF-C in lymph node positive prostate tumors.127  
 
In addition, VEGFR-3 was expressed by lymphatic endothelial cells and some 
blood vessel endothelial cells and, interestingly, also in the cytoplasma of the 
malignant epithelial cells. In accordance with the VEGF-C results, VEGFR-3 
expression was higher in lymph node positive tumors compared to lymph node 
negative tumors. Spearman’s rank correlation test showed a significant correlation 
between the VEGFR-3 score and the Gleason score. Previous to our publication, Li 
et al also reported of cytoplasmic expression of VEGFR-3,212 which suggests that 
the receptor might be involved in regulation of the tumor cells directly. Besides 
stimulating lymphangiogenesis, VEGF-C could therefore also possibly play a role 
in promoting tumor cell proliferation and subsequent invasion.  
 
The elevated expression of VEGF-C and VEGFR-3 in prostate cancer could be a 
reason for metastasis to regional lymph nodes and these factors could thereby be 
potential targets for anti-metastatic treatment of prostate cancer.  
 
 




Development of AI tumors is the main reason for death of prostate cancer and bone 
metastases are frequently detected at this stage. To develop new treatment 
strategies, molecular and cellular alterations that are associated with transition into 
androgen-independency and metastasis need to be clarified. To achieve this goal, 
well-defined animal models are essential. Our group has developed the AI cell line 
LNCaP-19, from the AD cell line LNCaP.209 The aim of the present work was to 
further characterize LNCaP-19 and to identify molecular and cellular alterations 
that are specifically related to the transition into androgen-independency, with 
focus on events related to the invasive and metastatic process.  
 
Transition into androgen-independency was associated with ability to grow without 
anchor in softagar and increased migratory capacity, which both are properties that 
promote establishment of metastatic foci. LNCaP-19 also displayed an increased 
cell adhesion to vitronectin and fibronectin, two major components of ECM and 
plasma. Migrating tumor cells form transient attachments to the matrix, often via 
integrins, and the results herein therefore indicate elevated levels of some integrin 
or other adhesive molecule in the LNCaP-19 cell line. However, no major 
differences in the integrin expression profiles between the cell lines were 
established. The only integrin subunit that was differentially expressed was the 
collagen binding integrin α2, which was elevated in LNCaP-19. Interestingly, a 
cadherin switch was identified in the LNCaP/LNCaP-19 tumor model. The tumor 
suppressor E-cadherin was downregulated in LNCaP-19 tumors compared to the 
LNCaP tumors. Instead, expression of the proinvasive factor N-cadherin was 
observed in LNCaP-19. Furthermore, LNCaP-19 displayed increased levels of 
MMP-9 and MT1-MMP compared to LNCaP. By modulating the ECM, these 
proteases make space for migrating tumor cells, allowing them to reach their final 
metastatic destination. Finally, we investigated if the molecular alterations had an 
effect on the actual capacity for the LNCaP-19 cells to invade blood vessels and 
reach the circulatory system. As expected, we found a higher proportion of blood 
vessels filled with tumor cells in the LNCaP-19 tumors than in the LNCaP tumors, 
showing that the alterations had a profound effect on the invasive potential of the 
AI tumors.  
 
From the results of this study we conclude that LNCaP-19 is a relevant model for 
studies on AI prostate cancer and invasion. This model could be valuable for 
evaluating new treatment strategies for AI prostate cancer. This study also 
demonstrates that transition into androgen-independency is directly associated with 
several prometastatic alterations.  
 
 




We were interested in studying the growth behavior of AD and AI prostate tumors 
in different microenvironments and at different androgen levels. The LNCaP and 
LNCaP-19 cell lines were used as a model system and tumor cells were implanted 
orthotopically or subcutaneously in intact and castrated immunodeficient mice. One 
purpose was also to evaluate MRI for monitoring orthotopic tumor growth in real-
time in the mice. 
 
Firstly, we investigated tumor growth in intact mice. We found that growth of the 
AI LNCaP-19 was suppressed in the prostatic microenvironment compared to the 
subcutaneous site. In contrast, the opposite was observed for the AD LNCaP. 
LNCaP grew rapidly at the prostatic site, which corresponds to the local growth of 
an AD primary tumor. These results imply that the prostatic environment influences 
AD and AI tumor cells differently. The retarded growth of AI tumors in the 
prostate corresponds to the clinical observations of the behavior of human prostate 
cancer. Local relapse of an AI tumors is relatively rare while deaths from metastatic 
disease are more common.213 We therefore suggest that AI tumors preferentially 
grow at other sites than the prostate.  
 
Next, we investigated the androgenic effects on the LNCaP-19 tumor growth in 
different settings. Interestingly, castration of the mice did not affect ectopic 
LNCaP-19 tumors but resulted in increased tumor growth in the prostatic 
environment. In addition, testosterone treatment of castrated mice with orthotopic 
LNCaP-19 tumors reversed the accelerated tumor growth. From these results it can 
be suggested that the local prostatic microenvironment, including the prostatic 
stromal cells, was responsible for the suppression of the AI LNCaP-19 tumors in 
the prostate. In contrast to the LNCaP-19 tumors, castration of mice with orthotopic 
AD LNCaP tumors resulted in impaired tumor development.  
 
Development and growth of the orthotopic tumors were easily followed over time 
with MRI. The tumor could be distinguished from the surrounding organs at all 
stages during the course of tumor progression. Tumors as small as 10 mm3 could be 
distinguished from the normal prostate and irregular shapes could be determined 
with a high degree of precision.  
 
To reveal factors that are responsible for the retarded growth of AI tumors in the 
prostate, a microarray experiment was performed. Three groups of LNCaP-19 
tumors were included as follows: 1: subcutaneous tumors from intact mice (sc 
intact), 2: orthotopic tumors from intact mice (ort intact) and 3: orthotopic tumors 
from castrated mice (ort castrated). Two comparisons were made; 1) “ort intact” 
versus “sc intact” and 2) “ort intact” versus “ort castrated”. We identified a set of 
genes that are the most plausible candidates for causing the slowly growing 
phenotype of LNCaP-19. Upregulated genes in the repressed tumors growing in 
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intact mice included ADAM metallopeptidase with thrombospondin type 1, motif 1 
(ADAMTS1), protocadherin 20 (PCDH20) and regulator of G-protein signaling 2, 
24 kDa (RGS2). ADAMTS1 is a multifunctional protein that inhibits 
angiogenesis,214 probably by sequestering VEGF215 and release of anti-angiogenic 
peptides from thrombospondin216 and ADAMTS1 has been shown to be 
downregulated in human prostate cancer.217 PCDH20 was recently identified as a 
tumor suppressor in non-small-cell lung cancer218 and RGS2 has been shown to 
inhibit AI activation of the AR.219 Downregulated genes in the repressed 
intraprostatic LNCaP-19 tumors included N-cadherin and neuronal cell adhesion 
molecule (NRCAM). N-cadherin and NRCAM are both cell adhesion molecules 
with a neuronal origin that facilitate migration and metastasis of tumor 
cells.165,179,190,220-222  
 
From this study, we conclude that prostatic stromal cells were responsible for the 
growth inhibition of orthotopic AI tumors. This is mediated through induction of 
genes inhibiting angiogenesis and tumor growth and suppression of genes 
promoting cell adhesion and metastasis. Furthermore, this study indicates that AI 
tumors do not thrive in the intact prostatic environment and supports previous 
clinical observations of frequent progression of prostate cancer as metastases in 
patients with castration-resistant disease. We also conclude that MRI is a useful 





N-cadherin has been implicated as an important prometastatic factor and its 
expression is elevated in several human malignancies.223 Most prostate cancer 
patients treated by ADT show an initial response, but the treatment effect is 
temporary and is often followed by regrowth of an aggressive and highly metastatic 
tumor. This study was conducted to investigate if N-cadherin is influenced by 
androgen deprivation and if its expression is associated with metastasis in prostate 
cancer. 
 
The results showed that expression of N-cadherin increased in absence of 
androgens in the AI LNCaP-19 tumor model in vitro and in vivo. In the AI PC-3 
cell line, N-cadherin was present but androgen deprivation did not result in 
enhanced N-cadherin expression. One possible explanation for the discrepant 
results is that LNCaP-19 expresses the AR and PC-3 does not, which might reflect 
the involvement of the AR in the regulation of N-cadherin. Increased levels of N-
cadherin are often accompanied by a concomitant decrease in E-cadherin and 
therefore, we investigated if E-cadherin decreased in absence of androgens in 
LNCaP-19. In subcutaneous LNCaP-19 tumors and in cultures in vitro, androgen 
deprivation did not alter the E-cadherin levels. In contrast, castration reduced E-
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cadherin levels in the orthotopic LNCaP-19 tumors. These results show that E- and 
N-cadherin are not directly associated with each other. It also shows the importance 
of the normal prostate tissue in controlling the expression of E-cadherin. We 
suggest that the intact prostate induces the E-cadherin expression, thereby keeping 
the differentiation of the AI tumors. We also investigated if increased N-cadherin 
was associated with EMT or neuroendocrine (NE) differentiation in the animal 
model. However, no clear associations could be established.  
 
Next, the N-cadherin findings were validated in human prostate cancer specimens. 
Accordingly, N-cadherin was more frequently observed in castration-resistant 
tumors compared to early, non-treated T1b tumors. There was also a significant 
correlation between the N-cadherin score and the Gleason score. Interestingly, 
when the castration-resistant group was divided in two based on the metastasis 
status of the patients, tumors from patients with established metastases had an 
increased N-cadherin score compared to patients without known metastases. To 
further assess the direct influence of castration on N-cadherin in human samples, its 
expression was investigated in a biopsy material taken sequentially during prostate 
cancer progression. The main finding was that N-cadherin increased in the prostate 
tumors already three months after initiation of ADT and its expression was 
sustained at the same level in the relapsed AI tumors. In contrast, we found no 
differences in E-cadherin staining in the biopsy material. 
 
From the results of this study it might be suggested that ADT directly influences 
the prostate cancer cells to acquire properties that make them more motile and 








One of the greatest challenges in the prostate cancer research field is to find ways 
to treat advanced prostate cancer. Today, locally advanced and metastatic prostate 
cancer is treated by ADT, which only offer a temporarily relief for the patients. 
Unfortunately, an AI prostate tumor eventually relapses. At present, there are few 
effective second-line treatments that can be initiated in the castration-resistant 
stage, and the response to these treatments is also highly variable. There is 
therefore an urgent need for new treatment options at this stage of disease. To be 
able to develop new therapeutic strategies for these patients, increased knowledge 




Characteristics of human AI prostate cancer 
One common feature of AI tumors is the presence of an activated AR, 
demonstrated by nuclear staining and expression of several androgen-regulated 
genes.51-53 Recent results indicate that despite castrate levels of testosterone in 
serum, intratumoral levels of androgens remain relatively high in castration-
resistant tumors. Intratumoral androgen levels have been reported to be increased in 
bone metastases from human castration-resistant tumors compared to untreated 
primary tumors224 and tumor progression of the LNCaP model after castration was 
associated with elevated intratumoral androgen levels.225 These observations 
indicate that prostate cancer cells can synthesize their own androgens. Accordingly, 
it was demonstrated that elevated intratumoral androgen levels were associated 
with increased levels of genes involved in the androgenic part of the steroid 
metabolism.224-226 Currently, there is a CYP17 inhibitor, abiraterone, in clinical 
trials for castration-resistant prostate cancer,227 which so far has shown promising 
results. In addition, AI tumors display an increased angiogenesis in comparison to 
AD tumors217,228 and anti-angiogenic therapy could be another promising approach 
to target AI prostate cancer. Another feature of AI tumors is NE differentiation. NE 
transdifferentiation is induced in response to androgen deprivation229,230 and is 
observed in bone metastatic lesions from prostate cancer patients231 and is 
significantly associated with death from prostate cancer.232 Recently, gene 
expression profiling of human AI tumors have been performed by some research 
groups. Unfortunately, there are no conclusive results regarding the characteristics 
of AI tumors from the different studies.233-235 As described in the introduction, 
prostate cancer, and especially AI tumors, is extremely heterogeneous, and even 
within the same patient, the phenotype of different metastatic deposits can vary 




reason for lack of agreement between different studies. The heterogeneity of AI 
tumors really comprises a major challenge in the development of new therapeutic 
concepts.  
 
Patients with castration-resistant prostate cancer most often have disseminated 
disease and not local tumor growth. Thus, these patients are not operated on a 
regular basis and tumor samples from the AI stage are therefore difficult to obtain, 
but collection of tissue has started to improve after the development of various 
rapid autopsy programs. Due to difficulties in obtaining human AI samples, 
experimental animal models of prostate cancer have been applied in the research. 
Reliable and well-characterized model systems of prostate cancer are of outmost 





Animal models of prostate cancer 
Prostate cancer only arises spontaneously in humans and in dogs and more rarely in 
rodents. Thus, spontaneous models of prostate cancer are few. Instead, there are 
some inducible prostate cancer models available in certain rat strains, where tumors 
can be induced by administration of chemicals or testosterone.236-238 Other existing 
prostate cancer models include transgenic models and xenograft models. The 
transgenic models, for example the TRAMP (transgenic adenocarcinoma of the 
mouse prostate) model, have the benefit of modeling the whole spectrum of the 
disease as it occurs, with progression from premalignant lesions through localized 
tumors to disseminated disease.239 Xenograft models, as we used in our studies, 
provide the opportunity to study human prostate cancer in an in vivo context in 
rodents. They also allow the assessment of reciprocal stromal-tumor cell 
interactions and metastasis. Over the years, several human prostate cancer cell lines 
have been established and used for inoculation in immune compromised mice. The 
classical human prostate cancer cell lines used in laboratories worldwide includes 
PC-3,210 DU-145240 and LNCaP.241 Different research groups have developed these 
cell lines further into several sublines with different androgen responsiveness and 
metastatic capacity. For instance, AI sublines have been developed in vitro by 
culturing AD LNCaP cells in absence of androgens, which was how LNCaP-19 
was established.209 AI cell lines have also been developed in vivo by growth in 
castrated mice.242 In addition, various sublines have been established from 
metastatic tissue in mice, which generate cell lines with increased propensity to 
form metastases.243 There are many factors to take into consideration when 
choosing cell line for implantation in mice. It is critical to understand the basic 
characteristics of the cell line and how relevant it is for the human disease. For 
instance, many human prostate cancer cell lines lack expression of AR and PSA, 




to correct cell line/model for the scientific problem that is being studied and 
different animal models can mimic various aspects of clinical prostate cancer. One 
drawback of the xenograft models is the use of immunodeficient mice, which 
leaves out the immune component that is of importance in tumor biology. Another 
drawback is that xenograft tumors grow rapidly and that not all tumor stages can be 
reproduced. Tumor cells are most often implanted at the subcutaneous site but it 
might be more relevant to implant the tumor cells in the correct anatomical site 
from where the cells origin, i.e. orthotopic implantation. A major problem with the 
existent xenograft models of prostate cancer is the rare formation of bone 
metastases. The underlying cause of this is not known. Because of this, special 
systems have been devised to study the growth of prostate cancer cells in bone, and 





MR as an imaging tool for monitoring tumor growth in 
mice 
An orthotopic tumor growth resembles the features of human prostate cancer more 
closely than subcutaneous models and is therefore preferable in many aspects. 
However, to be able to follow tumor growth, as well as the effects of treatment over 
time, sacrificing animals at different time points is usually needed. Thus, large 
cohorts of animals have to be included in longitudinal studies and each animal 
provides data for one time point only. In paper III we applied a non-invasive 
technique by using MRI to follow the growth of orthotopic tumors in real-time. 
This technique allows fast, precise and repetitive measurements of the tumor at 
different time points in the same animal. The use of MRI has a wide application in 
experimental studies of prostate cancer in animal models, including discrimination 
between normal prostate tissue and tumor244,245 and for determining intratumoral 




Transition into androgen-independency is associated with 
prometastatic properties 
The model system that comprises LNCaP and LNCaP-19 resembles human prostate 
cancer progression into androgen-independency in several ways. LNCaP-19 
displays increased angiogenesis, secretes PSA and has the capacity to grow under 
androgen deprived conditions.209 An advantage with the model system is that 
differences between the cell lines reflect tumor progression into androgen-
independency and are not due to heterogeneity between samples that are a common 




conclude that many invasive and metastatic traits are acquired during transition into 
androgen-independency. These included enhanced migratory capacity, ability to 
grow without anchor and increased adhesion to the ECM proteins fibronectin and 
vitronectin. In addition, transition into androgen-independency resulted in induction 
of the invasive promoting factors N-cadherin, MMP-9 and MT1-MMP and 
downregulation of the tumor suppressor E-cadherin in the LNCaP-19 cells, which 
are itself intriguing with regard to the fact that ADT is the only available choice of 
treatment for patients with advanced prostate cancer. The induction of metastatic 
traits in the LNCaP-19 cell line ultimately resulted in increased potential to invade 
tumor blood vessels (fig. 8). There is limited knowledge on the molecular basis for 
the invasion tumor cells into blood vessels. The maturation of tumor blood vessel is 
often limited, leaving vessels destabilized with poor pericyte coverage and this 
phenotype might facilitate tumor cell invasion. We248 and others249 have recently 
shown that the degree of pericytes coverage influences tumor cell invasion into 
blood vessels. In the LNCaP-19 tumors, we observed that blood vessels with less 





Figure 8: Transition of the AD LNCaP into AI LNCaP-19 involves several proinvasive 
alterations. LNCaP-19 cells displayed increased anchorage-independent growth, migratory 
capacity and adhesion to the ECM components vitronectin and fibronectin in comparison to the 
LNCaP cells. The LNCaP cells express the tumor suppressor E-cadherin on the cell surface, 
which could prevent detachment between adjacent cells and subsequent invasion into blood 
vessels. On the other hand, the LNCaP-19 cells express the proinvasive factors N-cadherin, MT1-
MMP and integrin α2 on their cell surface and induce the expression of MMP-9 from the 
surrounding stromal cells. Together, the changes induced at transition into androgen-





Results from paper II show that LNCaP-19 has the ability to complete the first steps 
in the metastatic cascade, i.e. detachment from surrounding tumor cells, migration 
through the tissue and intravasation into blood vessels to seed tumor cells into the 
circulation. In addition, recently obtained data also demonstrate that LNCaP-19 can 
complete the later steps of the metastatic cascade, which includes extravasation and 
colonization at the new site. The last step is the most challenging for the tumor cells 
and it has also been demonstrated that this is the rate-limiting step in the formation 
of metastases.87,88 After orthotopic implantation LNCaP-19 forms metastases to 
primary and renal lymph nodes and also to the lungs and kidneys. After intracardiac 
administration of tumor cells, metastases to the spine were observed. In addition, 
LNCaP-19 grows in the bone after intratibial injection and the established tumors 
showed an osteoblastic response. One important finding of our study is that AI 
tumor cells are more invasive than AD tumor cells, which suggests a direct link 
between induction of invasive and metastatic properties and androgen deprivation 
and subsequent development of an AI tumor. Exactly how the invasive program is 




AI tumors are suppressed in the prostatic 
microenvironment 
Interactions between stromal cells and tumor cells are of great importance in the 
progression of prostate cancer.72 The stromal cells influence the tumor cells and 
therefore varying tumor physiology and tumor properties can be observed 
depending on the site of growth.250,251 The results from paper III indicated that AI 
tumor cells did not thrive in the prostatic microenvironment. The observation is in 
accordance with clinical experience, where AI tumors rarely relapse locally in the 
prostate but rather as metastases.213 Our observation is also supported by 
experimental studies in mice from other groups. Decreased tumor growth at the 
orthotopic site compared to ectopic sites has recently been reported for an 
experimental AI prostate cancer model.252 Moreover, in the TRAMP model, 
castration of the mice promoted progression of the AI tumors at distant sites and to 
a lesser extent locally in the prostate.253 It has also been shown that the ability of 
the AI C4-2 tumors to metastasize to bone were higher when injected 
subcutaneously compared to orthotopically, which also illustrates the inhibitory 
role of the prostatic environment.254  
 
Castration results in a rapid regression of the normal epithelial cells and affects the 
secretion of androgen-regulated factors from the stromal cells. In paper III, 
inoculation of LNCaP-19 cells in the prostate of a castrated host resulted in 
increased tumor growth and it could therefore be suggested that the prostatic 
microenvironment secrets testosterone regulated factors that influence the growth 




play a vital role in controlling the epithelial cells, either in a positive or negative 
direction. It has been shown that the normal prostatic stroma responds to androgen 
treatment by restraining the proliferation of the epithelial cells.255 In addition, it has 
been shown that when the rat prostate Dunning tumors where grafted in presence of 
normal stromal mesenchyme it resulted in inhibition of tumor growth and induction 
of a more differentiated morphology.256,257 These studies illustrate that the normal 
prostatic environment controlled the tumor and could overcome the defective 
genetic alterations, resulting in tumors with less aggressive potential. Interestingly, 
the suppressed tumor growth of LNCaP-19 in the intact prostate (paper III) was 
accompanied with increased expression of E-cadherin (paper IV) when compared 
to E-cadherin expression in the fast growing tumors from castrated mice. 
Expression of E-cadherin is observed in differentiated epithelial tissues and thus, 
the results suggest that an intact prostatic environment keeps the AI tumors in a 
higher differentiation stage, resulting in a more controlled tumor growth.  
 
The suppressed tumor growth of LNCaP-19 in the intact prostate was most likely 
due to an upregulation of angiogenesis inhibitors and tumor suppressors, including 
ADAMTS1,214,217 PCDH20218 and RGS2.219 In addition, the prostatic 
microenvironment repressed genes that are known to be involved in cell adhesion 
and metastasis, which included N-cadherin165,179,190 and NRCAM.220-222 
Interestingly, many genes related to differentiation and migration of neuronal cells 
were suppressed by the prostatic tissue in the slowly growing LNCaP-19 tumors. 
Why a neuronal-like phenotype promotes and benefit tumor growth is presently not 
known. Various factors have been isolated from prostatic stromal cells that are 
likely to influence the growth of tumors.15,77,258 However, the factors that were 




Prometastatic alterations induced by ADT 
In our studies, we could show that N-cadherin was increased after androgen 
deprivation (paper IV) and subsequent transition into androgen-independency 
(paper II). N-cadherin was induced in response to androgen deprivation both in 
experimental and human prostate cancer. Based on our results from paper IV it is 
reasonable to believe that the AR plays a role in the suppression of N-cadherin, 
since no effects were seen in the AI cell line without AR. An ARE has been 
identified in intron 1 of the N-cadherin gene259 and it is possible that the repressed 
N-cadherin gene expression is attributed to a direct inhibition by binding of 
activated AR to this site. However, the ARE might not be involved in the regulation 
of N-cadherin, and there is also a possibility that the regulation is indirect through 
another androgen regulated factor. Similarly to N-cadherin, VEGF-C is also 
induced by androgen deprivation and recently it was shown that expression of 




Androgen deprivation therefore results in decreased NKX3.1 and increased VEGF-
C expression. Exactly how AR and androgens regulate N-cadherin are at present 
unknown and further studies are needed to be able to address this issue.  
 
In paper IV, we observed an upregulation of N-cadherin in human tumor samples 
already three months after initiation of ADT. At the same time, the PSA value had 
reached nadir in the majority of the patients and the tumor was in a regressed state. 
These findings might therefore indicate that elevation of N-cadherin was not due to 
transition into the AI stage, but was rather a direct consequence of androgen 
deprivation. However, another possibility is that despite the low PSA values, 
transition into androgen-independency could already have occurred and therefore 
increased N-cadherin could be one of the factors initiating the metastatic phenotype 
acquired by AI tumors. In the literature, N-cadherin is mostly described as a factor 
that promotes migration and metastasis of tumor cells. However, N-cadherin has 
also been reported to be involved in survival of tumor cells, via induction of anti-
apoptotic pathways.175,184 Consequently, induction of N-cadherin after ADT can 
promote a survival advantage for tumor cells at low androgen levels. With these 
results in hand it is tempting to speculate that ADT induces molecular alterations in 
the tumor cells that will give the tumor cells an advantage in forming metastases in 
the relapsed AI stage. Correspondingly, there are other reports in the literature 
supporting the possibility that androgen deprivation could induce the metastatic 
machinery in the cells. Nestin, which is an intermediate filament protein that has a 
role in migration and metastasis of tumor cells, are induced in response to androgen 
withdrawal.261 Similarly, expression of VEGF-C115,262 and MMP-9263 is upregulated 
in the absence of androgens.  
 
ADT is standard treatment for patients with locally advanced or metastatic prostate 
cancer. The benefits for the patients are indisputable and it has been suggested that 
ADT should be initiated in an early phase of the disease.41,42 In addition, clinical 
findings demonstrate that it is of importance to continue with ADT also in patients 
with relapsed AI tumors.44 However, conflicting data are reported in the literature, 
regarding the effects of androgen deprivation on the cellular level. Disruption of the 
androgen signaling pathway by ADT may results in deregulation of the cell control, 
which could contribute to the carcinogenic process. Early initiation of ADT might 
therefore speed the development of castration-resistant disease. In addition, it has 
been suggested that treatment with anti-androgens such as bicalutamide would 
induce alterations in the prostatic environment that promote emergence of AI 
tumors.264 In support of our findings, studies have shown that an intact androgen 
signaling pathway in prostate tumor cells decreased invasion and metastasis in 
animal models.265,266 In contrast, there are also reports showing that testosterone 
signaling via AR promotes invasion of prostate tumor cells in vitro.267 Because of 
the contradicting data in the literature, further studies emphasizing the molecular 





It has earlier been reported that N-cadherin is increased in poorly differentiated 
prostate cancer and that its expression correlates to Gleason score.188-190. In 
addition, in a recent study it was shown that N-cadherin expression in untreated 
prostate tumors was associated with pelvic lymph node infiltration and shorter time 
to skeletal metastases.165 Whether the increased N-cadherin observed after initiation 
of ADT in paper IV really leads to a poor prognosis and if it has a meaning for the 
propensity for tumor cells to form metastases remains to be clarified. However, a 
possible clue could be that patients with established metastases more frequently 
expressed N-cadherin. Increased levels of N-cadherin in poorly differentiated and 
castration-resistant prostate cancer specimens open the possibility to use N-
cadherin antagonists as second-line therapy for castration-resistant prostate cancer. 
At present, an anti-N-cadherin peptide, ADH-1 (Exherin™) is being evaluated in 
experimental animal models of cancer and in clinical trials against N-cadherin 
expressing tumors.268-271 This peptide disrupts N-cadherin cell adhesion, thereby 
preventing the adhesion to stromal components and neighboring tumor cells. The 
main effect of the disrupted N-cadherin adhesion is believed to work through 
increased apoptosis. Targeted therapy using an N-cadherin antagonist in 
combination with chemotherapy or other targeted therapies could be a novel 




The role of the lymphatic system for metastasis 
The blood circulatory system is clearly important in the dissemination of tumor 
cells. The contribution of the lymphatic system to the spread of tumor cells is 
however less obvious. There are certainly a variety of factors that influence if a 
tumor cell will spread via the blood or lymphatic system. In addition, the lymphatic 
vessels converge and empty its lymph into the venous part of the hematogeneous 
system. Consequently, there are interconnections between the two systems and 
therefore tumor cells can spread from one to the other. Most likely, dissemination 
of tumor cells in the two systems occurs in parallel.  
 
Tumor lymphangiogenesis has been intensively investigated during recent years. 
Today, there is great evidence that lymphatic vessels promote lymph node 
metastasis and presence of lymph node metastases is considered a poor prognostic 
sign in many types of cancer, including prostate cancer.98 In paper I, we could show 
that one of the main lymphangiogenic growth factors, VEGF-C, was more 
prominently expressed in prostate tumors from patients with presence of regional 
lymph node metastases than in tumors from patients without lymph node 
metastases. Our results are confirmed by studies from other investigators.127,272 We 
and others272 could not establish a correlation between VEGF-C and Gleason score, 




progression to a more dedifferentiated stage. Rather, it seems that VEGF-C 
contributes to tumor progression by proving a path for tumor cell escape via the 
lymphatic network. Corresponding to the VEGF-C results, the receptor VEGFR-3 
was also elevated in the lymph node positive tumors. We demonstrated presence of 
VEGFR-3 in the cytoplasma of the tumor cells, which was in accordance with a 
previous study published by Li et al.212 Possibly, the VEGFR-3 could promote 
tumor growth via an autocrine regulatory loop, but further studies are needed to 
reveal the significance of this finding. There are other reports that demonstrate 
expression of VEGF receptors in both cancer cell lines and solid human tumors.273-
279 In the prostate, VEGFR-1 and VEGFR-2 have been found to be expressed by 
malignant epithelial cells and the proliferation of the tumor cells could be driven by 
VEGF.280,281 In addition, it has been demonstrated that by inhibiting VEGFR-1,2 
and 3 expression from the tumor cells it resulted in decreased migratory capacity of 
the tumor cells and enhanced sensitivity to chemotherapy. The cytoplasmic 
receptors might therefore be involved in the survival of the tumor cells.282Although 
the function of tumor cell derived VEGF receptors are not completely understood, 
the concomitant expression of ligand and receptor suggests that the receptors 
mediate biological effects in an autocrine fashion. However, most reports regarding 
VEGFR-3 involves its expression by lymphatic endothelial cells, which is 
associated with presence of lymph node metastases in several types of cancer, 
including prostate cancer.128,283,284  
 
In paper I, it would have been relevant to study the lymphatic vessel density in the 
tumors but at the time we published the article, specific antibodies for any of the 
lymphatic markers lyve-1, podoplanin or prox-1, were not available. Other reports 
regarding lymphatic vessel density in prostate cancer have proven that presence of 
peritumoral lymphatic vessels and tumor cell invasion into peritumoral lymphatic 
vessels were associated with lymph node metastases.99,285,286 Because of the high 
physical pressure inside tumors there have been doubts if lymphatic vessels could 
penetrate into expanding primary tumors287,288 However, presence of functional 
intratumoral lymphatic vessels in the centre of the tumor has been reported by other 
groups.289 Thus, the issue whether intratumoral lymphatic vessels are functional is 
controversial and needs further investigations.  
 
The lymphatic system may play an active role in the metastatic process by directly 
facilitating recruitment of cancer cells into the vessels. However, exactly how this 
is accomplished is not known but several theories have been proposed. The 
simplest explanation for the metastasis enhancing effects of VEGF-C would be that 
by increasing number of lymphatic vessels, it results in increased surface contact 
area between invading cancer cells and the lymphatic vessels. In addition, there is 
experimental evidence that lymphatic endothelial cells secrete chemokines that 
could attract invading tumor cells to the vessels.92,290 There is no direct 




endothelium are required for entry into the lymphatic vessels. However, studies 
suggest that the mannose receptor 1 (MR-1) and common lymphatic endothelial 
and vascular endothelial receptor 1 (CLEVER-1) might be important mediators of 
cancer cell adhesion to the lymphatic endothelium.291 Another possible explanation 
could be that VEGF-C alters the lymphatic vessel permeability, thereby making the 
vessels more prone to promote metastases. To address the question how VEGF-C 
increases lymphatic dissemination of tumor cells, Hoshida et al used intravital 
microscopy to image the lymphangiogenic process and entry of tumor cells into the 
lymphatic vessels. From these studies they concluded that VEGF-C induced 
hyperplasia of the lymphatic vessels, thereby increasing the surface contact area for 
the invading tumor cells. In addition, VEGF-C increased the lymphatic flow rate, 
which enhanced the delivery of tumor cells to the lymph nodes and also increased 
the establishment of metastases.292  
 
There have been attempts to block lymphatic dissemination of tumor cells by 
introducing soluble VEGFR-3 in animal models of cancer.121,293,294 These 
experiments resulted in decreased lymphatic vessels around the tumor and in 
addition, suppression of lymph node metastases. In support of this, it has been 
shown that glucocorticoids, which have some benefits in the treatment of hormone-
refractory patients, suppress expression of VEGF-C and also tumor 
lymphangiogenesis.295 Blocking the VEGF-C/VEGFR-3 signaling axis therefore 
seem to be one reasonable approach to combat the metastatic spread of tumor cells. 
Collectively, targeted therapy directed against VEGF-C and the formation of 
lymphatic vessels in the tumor may interfere with the initial steps of the lymphatic 








• VEGF-C and VEGFR-3 are elevated in lymph node positive prostate tumors. 
Thus, they could play an important role in promoting metastasis to regional 
lymph nodes. Blocking the VEGF-C signaling axis may therefore be a 
potential new treatment strategy for inhibiting dissemination of tumor cells 
via the lymphatic system.  
 
• Transition into androgen-independency is associated with induction of 
several proinvasive and metastatic properties.  
 
• The model system with LNCaP-19 mimics AI human prostate cancer in 
many aspects and is therefore a relevant model for studies on AI prostate 
cancer and invasion. 
 
• AI prostate cancer cells are growth inhibited in the prostatic environment, 
probably by androgen-regulated factors that originate from the prostatic 
stromal cells. This finding corresponds with the clinical observation that 
human castration-resistant prostate cancer mainly progress as metastases and 
not locally in the prostate.   
 
• MRI is a convenient imaging tool for monitoring growth of orthotopic 
prostate tumors in mice.  
 
• ADT induces expression of the proinvasive factor N-cadherin in prostate 
tumor cells. This might indicate that androgen deprivation induces molecular 
alterations in the cancer cells, which could promote the invasive and 
metastatic phenotype observed in patients with castration-resistant prostate 
cancer.  
 
• Expression of N-cadherin increases with tumor grade and is also associated 
with metastasis in human prostate cancer. N-cadherin could be a possible 








Prostatacancer är den vanligaste cancerformen bland män i Sverige och varje år 
diagnostiseras ca 9000 nya fall. Det är även den cancerform som orsakar flest 
dödsfall hos svenska män, och årligen dör ca 2300 män av prostatacancer i Sverige.  
 
De flesta prostatatumörer växer långsamt, men det finns också de tumörer som är 
mer aggressiva. Det manliga könshormonet testosteron reglerar till en början 
tillväxten av en prostatatumör och därför säger man att tumören är androgen-
beroende. Tillväxten av prostatacancer kan därför bromsas genom att avlägsna 
testosteronet i kroppen. Detta görs genom kastration. Behandlingen fungerar till en 
början väl och leder till en minskad tumörstorlek. Dock är denna behandling inte 
botande och i regel återkommer cancern efter något år. I detta stadium regleras 
tumören inte längre av testosteron och den benämns därför som androgen-
oberoende. Androgen-oberoende tumörer är aggressiva och ofta bildas metastaser 
(eller så kallade dottertumörer) i lymfkörtlar och i skelettet. I dagsläget finns ingen 
tillfredsställande behandling i detta skede av sjukdomen och prognosen är dålig. 
För att kunna utveckla nya behandlingsstrategier för androgen-oberoende 
prostatacancer krävs ytterligare kunskap om egenskaperna hos dessa tumörer. Detta 
avhandlingsarbete har fokuserat på att kartlägga egenskaper hos androgen-
oberoende prostatacancer, med fokus på de egenskaper som är förknippade med att 
tumören kan sprida sig till andra organ och bilda metastaser.  
 
I studierna användes ett experimentellt modellsystem med androgen-beroende och 
androgen-oberoende celler från prostatacancer. Cellernas egenskaper studerades i 
cellodlingssystem samt i försöksdjur. Diverse molekylärbiologiska metoder 
användes för att utvärdera resultaten. För att konfirmera resultaten från 
djurstudierna inkluderades även material från patienter med prostatacancer. 
 
Inledningsvis användes modellsystemet för att studera vilka förändringar som sker i 
tumörcellerna när de övergår från att vara androgen-beroende till att vara androgen-
oberoende. Ett flertal förändringar i de androgen-oberoende tumörcellerna 
identifierades, däribland en ökad rörlighet och en ökad förmåga att invadera 
blodkärl i tumörer. Ytterligare studier påvisade en ökning av proteiner som främjar 
bildningen av metastaser (N-cadherin, MMP-9 och MT1-MMP) och en minskning 
av proteiner som hämmar tumörtillväxt (E-cadherin), i androgen-oberoende 
cancerceller.  
 
I nästa studie undersöktes hur olika typer av tumörer påverkades av den omgivande 
miljön i prostatan. Resultaten visade att androgen-oberoende tumörceller 




utsöndrar olika substanser som påverkar tumörcellerna i modellen så att de växer 
långsammare. Resultaten från denna studie överensstämmer med det kliniska 
förloppet hos många patienter. Hos patienter med androgen-oberoende 
prostatacancer sker tillväxten främst i form av metastaser i skelettet och inte av den 
ursprungliga tumören i prostata.  
 
I de inledande studierna identifierades N-cadherin som en intressant faktor som 
börjar produceras när tumörcellerna blir androgen-oberoende. N-cadherin är ett 
protein som främjar bildningen av metastaser. I de efterföljande studierna 
undersöktes hur N-cadherin påverkades av kastrationsbehandling. Huvudfyndet var 
att N-cadherin ökade i tumörerna efter att testosteronet hade avlägsnats, både i 
djurmodeller och i prov från prostatacancerpatienter. Förekomst av N-cadherin i 
prostatacancerproverna var även förknippat med metastaser i skelettet. Denna 
studie visar att kastrationsbehandlingen leder till att N-cadherin börjat produceras 
från cancercellerna. En blockering av N-cadherin skulle därför kunna komplettera 
kastrationsbehandlingen och därigenom förbättra effekterna av denna.  
 
Prostatacancer sprider sig ofta till lymfkörtlarna och därför undersöktes vilken 
betydelse det lymfatiska systemet har för denna process. VEGF-C är ett protein 
som främjar tillväxten av lymfkärl. Fler lymfkärl runt tumören kan i sin tur öka 
risken för att cancercellerna ska använda sig av dessa för att sprida sig vidare i 
kroppen. I studien analyserades förekomst av VEGF-C i prostatacancerprov från 
patienter. Resultaten visade att nivån av VEGF-C var högre i de tumörer som hade 
spridit sig till närliggande lymfkörtlar jämfört med de tumörer som inte hade spridit 
sig till lymfkörtlarna. En möjlig väg att hämma spridningen av tumörceller i 
kroppen via lymfkärlen skulle därför kunna vara att blockera VEGF-C.  
 
Sammantaget visar detta avhandlingsarbete att utvecklingen av androgen-
oberoende prostatacancer är associerat med ett flertal förändringar i tumörcellerna 
som främjar metastasering. Hämning av N-cadherin och VEGF-C skulle kunna 
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